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Trachoma is a blinding disease usually caused by infection with Chlamydia trachomatis (Ct) serovars A, B, and C in the upper tarsal
conjunctiva. Individuals in endemic regions are repeatedly infected with Ct throughout childhood. A proportion of individuals
experience prolonged or severe inflammatory episodes that are known to be significant risk factors for ocular scarring in later
life. Continued scarring often leads to trichiasis and in-turning of the eyelashes, which causes pain and can eventually cause
blindness. The mechanisms driving the chronic immunopathology in the conjunctiva, which largely progresses in the absence of
detectable Ct infection in adults, are likely to be multifactorial. Socioeconomic status, education, and behavior have been identified
as contributing to the risk of scarring and inflammation. We focus on the contribution of host and pathogen genetic variation,
bacterial ecology of the conjunctiva, and host epigenetic imprinting including small RNA regulation by both host and pathogen in
the development of ocular pathology. Each of these factors or processes contributes to pathogenic outcomes in other inflammatory
diseases and we outline their potential role in trachoma.
1. Introduction
Sightsavers International estimates that every 15 minutes a
person loses sight as a result of trachoma [1]. As such, tra-
choma remains the world’s leading infectious cause of blind-
ness despite significant efforts to control and eliminate the
disease [2]. Trachoma is currently considered endemic in
51 countries worldwide and only seven formerly endemic
countries have reached target elimination thresholds [2]. The
Alliance for theGlobal Elimination of Blinding Trachoma has
set the goal of 2020 for the elimination of trachoma. The aim
is to control trachoma through the implementation of surgery
for trichiasis, antibiotics to treat infection, facial cleanliness,
and environmental improvements to reduce transmission
(SAFE). Currently 31 trachoma endemic countries implement
SAFE, which is effective in controlling trachoma if well con-
ducted. Azithromycin is the antibiotic of choice used in mass
drug administration (MDA) programmes for trachoma con-
trol. There are additional beneficial effects of azithromycin
MDA, including reduced all-causemortality [3] and potential
to reduce clinical disease through its anti-inflammatory
properties [4]. There remains a need to pursue vaccine
development as there are circumstances when SAFE is poorly
effective and there is uncertainty about its universal applica-
tion. The lack of randomized controlled trials examining the
effectiveness of the F and E components for the interruption
of transmission, alongside the historical lack of molecular
laboratory tools able to identify transmission events, raises
questions on the basic understanding of their effectiveness.
Additional concerns with the A component include the
long-term use of antibiotics in populations where MDA has
failed to control disease [5], introduction of resistance in
other bacterial species [6], and the continued progression of
scarring and trichiasis in populations where MDA has been
implemented [7]. It is also not currently understood whether
effective mass treatment leads to arrested immunity and it
is unclear what impact the elimination of ocular chlamydial
exposure in childhood might exert later in adolescent and
adult urogenital disease. Chlamydiae can reside in the gastro-
intestinal tract in the absence of clinical disease and this has
led to the suggestion that azithromycin treatment failures (at
least in urogenital disease) may be because gastrointestinal
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Chlamydiae are refractory to azithromycin treatment and can
act as a source for autoinoculation [8, 9]. A vaccine offering
effective long-term protection against disease in both ocular
and urogenital chlamydial disease therefore remains desirable.
Trachoma is initiated by infection of the tarsal conjunc-
tiva with the intracellular bacteria Chlamydia trachomatis
(Ct).There are a number of classification systems for the clin-
ical signs of trachoma. Under the WHO simplified grading
system, the presence of five or more follicles on the conjunc-
tival surface is classified as trachomatous inflammation fol-
licular (TF). Ct infection is independently associated with TF
(OR = 11.2 (95% CI 6.9–18.1) [10]), although this value varies
between populations depending on disease sign prevalence
and becomes disassociated from TF once prevalence is low.
Repeated Ct infection in endemic communities can trigger
chronic conjunctival inflammation (trachomatous inflamma-
tion intense, TI) in some individuals, causing conjunctival
fibrosis (trachomatous scarring, TS). Progressive fibrosismay
lead to entropion, inward turning, or misdirected lashes
(trachomatous trichiasis, TT), all of which abrade the corneal
surface. This abrasive damage may lead to corneal opacity
(CO) and blindness. Figure 1 shows reflective in vivo confocal
microscopy scans, histology sections, and photographs of
the tarsal conjunctiva that illustrate the changes in tissue
architecture that occur in the different stages of trachomatous
disease.
The human trachoma vaccine trials that took place in
the 1960s concluded that some short-term strain-specific
protection from infection was induced, amidst concerns that
pathology was exacerbated in some cases, supported by data
frommonkeymodels [13].The data from these large placebo-
controlled trials has been recently reinterpreted in the context
of current grading systems and our current knowledge of
disease pathogenesis. Only trial III in The Gambia recorded
evidence of conjunctival scarring. Two doses of prophylactic
vaccination made from two live strains in mineral oil were
given three weeks apart to children aged 0–4 years.There was
no protection from active trachoma; however the vaccinated
group had a reduced prevalence of scarring disease two years
later [14]. When all three Gambian trials are reviewed in the
context of what is now known about disease pathogenesis,
vaccine-induced exacerbation of disease may not be a signifi-
cant concern, raising hopes that current vaccine formulations
may be successful [15, 16].
2. Immunopathology of Trachoma
Despite extensive research, the mechanistic link between
chronic inflammation and progressive scarring remains elu-
sive [7].The scarring observed in both trachoma and urogen-
ital disease is thought to be a result of the host response to
infection rather than a direct effect of the bacteria. Defining
the features of protective versus pathogenic immunological
responses in chlamydial disease (reviewed in [17]) is crucial
to the understanding of disease and for efficacious vaccine
design.
Currently, two models have been put forward to explain
the immunopathogenesis of chlamydial disease: the immu-
nological and cellular paradigms. The traditional immuno-
logical paradigm implicates the adaptive immune system.
Initial studies on chlamydial infection found that repeated
infection exacerbated inflammation and that inflammatory
pathology continued in the absence of Ct. At first, a delayed
type hypersensitivity (DTH) reaction triggered by a chlamy-
dial antigen was hypothesized. The chlamydial heat shock
protein 60 (HSP60) was considered a candidate antigen to
trigger DTH but was not found to exacerbate pathology
when tested in a guinea-pig model [18]. Antibodies to HSP60
predicted a 2-3-fold higher risk of Ct pelvic inflammatory
disease (PID) in humans and higher levels of antibodies
specific to HSP60 were found in women with the most
severe forms of urogenital disease [19]. Likewise antibodies to
HSP60 were associated with tubal factor infertility (TFI) and
inflammatory trachoma [20, 21]; however it remains unclear
whether these antibodies cause pathology or are a result of a
greater number or more severe episodes of infection. More
recent screening of sera from trichiasis patients and controls
detected differential patterns of antibody recognition for a
number of Ct antigens; however HSP60 responses were not
significantly different [22].
Previous research demonstrated that individuals with
scarring trachoma had Th2 patterns of cytokine expression
[23], whereas those with strong Th1 responses efficiently
cleared infection [24].This opposed theDTH theory and sug-
gested that a Th2 response either was ineffectual at clearing
infection or led to enhanced pathology and that CD4+ Th1
IFN𝛾 responses were a key element of protective immunity
in trachoma. Both CD8+ and CD4+ T cell infiltrates are asso-
ciated with the conjunctival follicles that are characteristic of
TF; however CD4+ T cells are thought to outnumber CD8+
[25]. NK cells have more recently been identified as a major
early source of IFN𝛾 in response to Ct [26]. Despite the pri-
mary function of CD8+T cells in defense against intracellular
pathogens, data frommurine models previously found a lim-
ited role for CD8+ T cells in anti-Ct immunity [27]. Recent
evidence in the macaque model of trachoma challenges this
theory and suggests that depletion of CD8+ T cells can abro-
gate protective immunity [28]. Characterization of the roles
of each of these cell types in chronic scarring trachoma has
proved difficult to address, however, largely due to the natural
history of scarring disease.
Stephens suggested an alternative model of disease [29]
in which epithelial cells at the infection site play a central
role as mediators of the innate immune response. Epithelial
cells infected with Ct secrete a number of proinflammatory
cytokines and growth factors, such as IL-8, GRO𝛼, IL-1𝛼,
IL-6, and granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF). The secretion of these cytokines is delayed
compared to the kinetics of secretion upon infection with
other invasive bacteria and persists throughout the 2–4-day
developmental cycle of Ct. The secretion of IL-1𝛼 by infected
cells was shown to upregulate proinflammatory cytokine pro-
duction by neighboring uninfected cells, promoting a strong
inflammatory response [30]. Lymphocytes of the adaptive
immune system are attracted to the infection site by the
chemotactic gradient and subsequent infections include
memory populations that amplify the response. Ct infected
cells also secreted the profibrotic cytokine IL-11, a member of
the IL-6 family [31, 32]. Recent evidence from a primary-like
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Figure 1: Images from a normal healthy eye (a–d) and from individuals with follicular trachoma (e–h), trachomatous scarring (i–l), and
trichiasis and progressive scarring (m–p). (a), (e), (i), and (m) are photographs of the tarsal conjunctiva showing normal appearance (a),
papillary inflammation and follicles (e), bands of trachomatous scarring (i), and extreme trichiasis and corneal opacity (m). (b), (c), (f), (g),
(h), (j), (k), and (l) are in vivo confocal microscopy images of the tarsal conjunctiva at various depths (the bar represents 50𝜇m). A moderate
number of inflammatory nuclei are present in the subepithelium of a healthy eye (b), whereas a higher number are present in trachomatous
inflammation (f). Follicles can be seen in (g) and (h). The connective tissue of the healthy conjunctiva is amorphous (c), whereas successive
grades of trachomatous scarring are seen as a heterogeneous clumpy appearance (j), defined tissue bands that make up <50% of the scan
area (k), and defined bands that make up >50% of the scan area (l). (d) and (n–p) are histological images of tissue scarring using polarized
light (original magnification ×100). In the healthy conjunctiva, collagen fibers are parallel (arrows) with the surface epithelium (d), whereas
progressive disorganization of this appearance is observed in scarring (n–p). Images are kindly provided with permission from Matthew
Burton and Victor Hu and are adapted from Hu et al. 2011 [11] and Hu et al. 2013 [12].
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polarized epithelial cell model showed that IL-11 was secreted
preferentially from the basolateral membrane and IL1ra from
the apical membrane in Ct infected cells [33]. The T cell
chemokines RANTES and IP10 were also downregulated in
productively Ct infected cells, suggesting that Ct attempts to
avoid stimulation of the immune response in order to main-
tain its intracellular niche, potentially leading to longer infec-
tions and chronic pathology [33]. Recent genome-wide scale
array studies from clinical samples support Stephens’s hypo-
thesis. Expression profiling of children in The Gambia with
active trachoma versus healthy controls revealed a strong up-
regulation of the innate immune response [34]. Along with
the expected infiltration of neutrophils, lymphocytes, and the
inflammatory cytokine pathways consistent with histopathol-
ogy [35], the natural killer (NK) cell responsewas also enhanced.
A transcriptome study conducted in Ethiopian adults with
either trachomatous trichiasis (TT) or TT with inflammation
(TTI) versus healthy controls found that despite less than
1% Ct infection prevalence, markers of ongoing subclinical
inflammation and tissue remodeling were evident in the
TT group and were more pronounced in the TTI group
[36]. These markers were consistent with an activated and
proinflammatory epithelium.There was a lack of evidence for
a profibrotic Th2 response and a very limited Th1 response.
Subsequent targeted quantitative-PCR studies have reempha-
sized the role of the innate immune response in trachoma in
both children and adults [37, 38].These studies found antimi-
crobial peptides psoriasin (S100A7), DEFb4A, and SAA1,
inflammatory cytokines IL17, IL1𝛽, and TNF, inflammatory
chemokines (CCL18 and CXCL5), MMPs, and CTGF were
upregulated in trachomatous disease. Increased IL17 expres-
sion was highlighted as characteristic of active trachoma and
is thought to coordinate the proinflammatory response [37].
Overall these studies suggest that clearance ofCt infection
requires an appropriate acute Th1 response with IFN𝛾 and
CD8+ T cells. They also support the case for the central
role of epithelial cells in ongoing trachomatous inflammation
and pathogenesis that leads to TT. This would imply that
neither the cellular nor the immunological paradigm can
fully explain disease but that active cross talk between
cellular (innate epithelial cell responses) and immunological
(adaptive immunity) systems is required.
3. Host Genetic Association
Studies and Trachoma
The assumed link between immune driven inflammation and
conjunctival scarring and its blinding sequelae led to the
first genetic association studies which focused on immune
response genes. Immune response genes located within the
Major Histocompatibility Complex (MHC) drive the adap-
tive cellular response and initial studies focused on the asso-
ciation of trachomatous scarring disease with alleles in HLA
class I and class II loci. The intracellular nature of chlamy-
dial infection suggested that class I restricted CD8+ T cell
responses would be important in controlling infection and
that these might be related to later scarring disease. MHC
class II loci would be expected to contribute by defining the
profile of anti-Ct antibody responses and cytokines via CD4+
class II restricted T cells.
The first reported genetic association study in trachoma
in Gambians [39] found evidence that a specific HLA class
I serological determinant of the HLA-A2 supertype (HLA-
A28) was associated with scarring trachoma (OR = 1.88,
𝑃 = 0.046) and observed that approximately 26% of scarring
cases had HLA-A28, compared to 16% of controls. HLA-A28
is made up of at least 3 molecular subtypes (HLA-A∗68:01,
HLA-A∗68:02, and HLA-A∗69:01), of which HLA-A∗68:02
was thought to be the most frequent allele in Gambians. In
a subset analysis of a limited number of samples from the
same study, molecular typing showed that the HLA-A∗68:02
allele was strongly associated with scarring trachoma (OR =
3.14, CI 1.32–7.44, and 𝑃 = 0.009). No alleles of either of the
MHC class II genes, HLA-DRB1 or HLA-DQB1, were found
to be associatedwith scarring. Antibody responses to chlamy-
dial HSP60 were positively correlated with the allele HLA-
DRB1∗07:01 (OR = 2.6, 𝑃 = 0.02) and negatively corre-
lated with both HLA-DQB1∗03:01 (OR = 0.42, 𝑃 < 0.001)
and HLA-DQB1∗05:01 (OR = 0.55, 𝑃 = 0.046) [40]. Later
studies also linked HLA class II alleles to anti-Ct antibody
prevalence and quantity in the clinical context of sexually
transmitted Ct infections [41, 42].
It had previously been shown that synthetic peptides
based on chlamydial sequences (MOMP and HSP60) could
elicit HLA-B8 and HLA-B35 restricted CD8+ CTL responses
in peripheral blood of individuals from trachoma endemic
regions [43]. In an attempt to link the observedHLA-A∗68:02
association to an effector mechanism, a follow-up study [44]
investigated whether HLA-A∗68:02 restricted CD8+ CTLs
or IFN𝛾 producing cells were associated with Ct specific
immune responses in a small number of scarring cases and
disease-free controls. Peptides from 3 chlamydial antigens
that were predicted to bind HLA-A∗68:02 were used to
stimulate cells but no chlamydia-peptide specific responses
were detected. This led the authors to suggest either that
the peptides that were chosen did not represent natural
epitopes or that HLA-A∗68:02 restricted CD8+ T cells were
not important mediators in ocular disease. An alternative
experimental approach and one that did not require in vitro
restimulation used HLA-A2-MOMP tetramers and found
that increased frequencies of CD8+ tetramer positive cells
were coincident with current ocular Ct infection and longer
durations of infection [45]. Effector functions of these cells
were not investigated but it was noted that the tetramers
used to identify cells also bound to the TCR of HLA-A28
restricted T cells. This supported a model under which the
HLA-A∗68:02 allele might contribute to scarring disease via
prolonged or chronic ocular infections.
Outside of trachoma, antichlamydial CD8+ MHC class
I restricted cells have been clearly demonstrated in murine
models [46] and in humans exposed to urogenital infections
[47]. Recently there has been a resurgence of interest in the
importance of CD8+MHC class I restricted T cells, following
work in a murine model of urogenital disease [48] and in
vaccinated monkeys [49]. Following vaccination with the
plasmid-free attenuated strain of Ct, monkeys with a com-
monMHC class II haplotype (M1) were protected from viru-
lent ocular challenge. Subsequent work found that protection
was mediated through CD8+ T cell recognition of soluble
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chlamydial antigens [28] and not through class II restricted
CD4+ T cells. Most recently, an immune-proteomic screen-
ing approach in mice showed that only a small percentage
(∼3%) of the Ct proteome is processed for presentation by
MHC class IImolecules.Ct proteins that were processedwere
the expected immunodominant proteins such as MOMP,
PmpE, PmpF, and PmpG and were presented on a wide range
of I-A and I-E MHC haplotypes [50]. The immunogenicity
of these proteins was also subject to both MHC class II
selection and chlamydial peptide sequence diversity. Overall,
this suggests that studies of sufficient size and power to
account for the high degree of polymorphism and small effect
size are required to further investigate HLA class II dis-
ease susceptibility. Overall, reports of associations between
human MHC polymorphisms and chlamydial infection and
disease have been inconsistent and have not identified a
specific causal pathway. Collectively these studies do suggest
an important but complex role for the MHC in chlamydial
host resistance and disease.
Following the early MHC class I and class II genetic
association studies in Gambians, a trachoma-HLA associa-
tion study was conducted in Omanis using a serologically
based typing system.This found some evidence of association
between TT and the HLA class II DR16 and DR53 antigens
[51]. Further studies in Tanzanians [52] found that trichiasis
was less common in women carrying HLA-DRB1∗11 alleles
(OR = 0.48, CI 0.26–0.90, and 𝑃 = 0.02) and more com-
mon in those carrying HLA-B∗07 (OR = 3.26, CI 1.42–7.49,
and 𝑃 = 0.004) or HLA-B∗08 (OR = 5.12, CI 1.74–15.05, and
𝑃 = 0.001). More recently, a much larger study in Gam-
bian families also highlighted the association between HLA-
B∗08:01 alleles and scarring [53], but analysis based on cur-
rent knowledge of the HLA system would suggest that HLA-
B∗08:01 could be a proxy marker for the HLA-C epitope of
the Killer Cell Immunoglobulin-like Receptors (KIRs). This
epitope is defined by a dichotomous amino acid polymor-
phism at position 80 of the HLA-C heavy chain [54]. HLA-C
alleles carry Asn80 and are designated C1 whilst those with
Lys80 are C2. The HLA-C KIR epitope determines which
KIR can bind the ligand, with KIR2DL1 binding to HLA-
C2 and both KIR2DL2 and KIR2DL3 binding to HLA-C1
[55–57]. KIR are a polymorphic family of membrane-bound
immune-receptors found onnatural killer (NK) cells [58–60],
where they are usually considered to control the licensing
[61] and responsiveness [62, 63] of the NK cytotoxic immune
response. KIRs are also present on NK-T cells and T cells [64,
65], though the functional contribution of KIRs to T cell reac-
tivity is relatively less well studied [66, 67]. The finding that
HLA-C2 was a significant predictor [53] of increased risk of
scarring in Gambian families (ORC1/C2 = 2.29, 𝑃C1/C2 =
0.0061 | ORC2/C2 = 3.97, 𝑃C2/C2 = 0.0004) further sug-
gested a role for NK cells in trachomatous scarring. Epistatic
effects were observed since KIR (Chromosome 19) genotype
modified the risk of scarring depending on HLA-C (Chro-
mosome 6) genotype; HLA-C2 showed additive gene dosage
effects and individuals carrying both KIR2DL2 and KIR2DL3
had the highest relative risk (ORC1/C2 = 2.33, 𝑃C1/C2 = 0.1 |
ORC2/C2 = 5.95, 𝑃C2/C2 = 0.0025). NK cells are likely to be
important in the initial host response to ocular challenge,
since it has been shown that they are the main cellular source
of IFN𝛾 in response to in vitro elementary body stimulation
[26].There was no evidence in the study of scarring trachoma
in Gambian families that the previously identified HLA-
A∗68:02 allele was associated with early scarring (𝑃 = 0.27).
MHC class I and class II association studies were also
extended into class III loci. A polymorphism in the tumour
necrosis factor (TNF) promoter region was found to asso-
ciate with scarring under an additive model (ORA/G = 1.59,
ORA/A = 3.4, and 𝑃 = 0.03) [68]. Whilst scarring disease
was also associated with increased detection of TNF protein
in tear fluid (ORadd = 2.5, 𝑃 = 0.013), TNF levels in the tear
fluid did not associate with the genotypes of the TNF-308
polymorphism. A later study of trichiasis patients and con-
trols found an association between TNF-308A and disease,
whichwas significant under a dominant, rather than additive,
genetic model (ORdom = 1.52, 𝑃 = 0.016) [69]. These
later data also suggested evidence for heterozygote advantage
(ORA/G = 1.48, 𝑃 = 0.048 | ORA/A = 1.11, 𝑃 = 0.12) in the
context of a simple genotypemodel; however adjustments for
multiple testing were not included. Lymphocytes from TNF-
308A individuals had increased TNF secretion in vitro in
response to challenge with Ct elementary bodies. Curiously,
the TNF-308A polymorphism has also been identified [70]
as a protective factor in trichiasis (ORA/G = 0.45 [0.25–0.81],
𝑃 = 0.008 | ORA/A = 0.19 [0.04–1.08], 𝑃 = 0.062) in a study
that also identified homozygosity at a lymphotoxin alpha
(LTA) polymorphism (LTA252 ORA/A = 0.25 [0.09–0.63],
𝑃 = 0.004), heterozygosity at an Interleukin 9 polymorphism
(IL9-T113M ORC/T = 0.25 [0.1–0.64], 𝑃 = 0.004), and hete-
rozygosity at the vascular cell adhesion molecule 1 (VCAM1,
OR = 0.47 [0.25–0.86], 𝑃 = 0.015) as protective factors for
trichiasis [70]. The same authors suggested that epistasis
between the polymorphisms was potentially key to unrav-
eling the host genetic background of trachoma. TT risk
increased substantially (OR = 13.5, 𝑃 = 0.001) when the
TNFA (-308G), VDR (intron G), IL4R (50V), and ICAM1
(56M) polymorphisms were considered as genetic constella-
tions under a “logic regression” model [70], but the number
of samples contributing to this analysis was small (controls
𝑛 = 232 and TT 𝑛 = 135).
A series of studies used SNP genotypes and linkage dis-
equilibrium data to predict haplotypes and then carried out
haplotype based association tests in genes including IFN𝛾
[71], IL8 [72], IL10 [71, 73], haptoglobin (HP),GM-CSF2 [72],
and matrix metalloproteinase 9 (MMP9) [74]. The MMP9
gene is consistently differentially expressed between cases and
controls of several stages of trachomatous disease [34, 36]. A
study of the IL8/CSF2 loci [72] also noted some evidence for
epistatic interactions between polymorphisms inMMP9 and
each of the IL8 and CSF2 genes. Other epistatic interactions
were also found in the same dataset, in particular, anMMP9-
IL10 interaction (Figure 2). In the analysis of a cohort of 651
scarring case-control pairs, main effects for the IL10-1082
allele were null; however interaction between IL10-1082 and
MMP9 Q279R contributed to risk. The protective effects of
the MMP9 Q279R G allele were transformed to risk in the
copresence of a SNP (IL10-1082) tagging the trachoma risk hap-
lotype (IL10-3575A∼IL10-1082C∼IL10-592G∼IL10+5009G).
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Figure 2: Evidence for MMP9-IL10 epistasis in Gambians with tra-
chomatous scarring. The protective effect of MMP9 allele (Q279R)
is modulated by host genetic background at the IL10 locus such that
protective effects of the G allele are lost in the presence of either
of 2 minor frequency risk alleles (IL10-1082C or IL10-3575A). The
interaction between these nonallelic genes (or risk genotypes) has a
dominant effect over other combinations. The interaction between
risk genotypes was examined by conditional likelihood ratio tests
(LRT) (main effects) log p/1 − p = a + b (SNP1) + c (SNP2).
Interaction terms were defined as Log p/1 − p = a + b(SNP1) +
c(SNP2) + d(SNP1∗SNP2) and when significant identified statistical
epistasis. This approach was applied to 651 Gambian case-control
pairs of TS. The MMP9 Q279R and IL10-3575 loci showed strong
evidence for statistical interaction affecting risk of TS (LRT 𝜒2 =
7.23, 𝑃 = 0.007). Carriers of the (protective) MMP9 Q279R G
allele who also had the IL10-3575Aminor allele were at significantly
increased risk of TS (OR = 1.83 (1.06–3.19)) when compared to
subjects with the IL10-3575 T allele (common allele) (OR = 0.84
(0.69–1.02)). The IL10-1082 C minor allele in combination with the
MMP9Q279R G allele had an increased risk of TS (OR = 1.51 (1.02–
2.24)) relative to IL10-1082 C in the presence of theMMP9Q279R A
allele (OR=0.82 (0.67–1.01)) (LRT𝜒2 = 7.53,𝑃 = 0.006 for the inter-
action between the IL10-1082 and MMP9 risk alleles). Interaction
between IL10-1082 and MMP9 Q279R affects risk despite the null
single SNPmain effect for IL10-1082 [71].The individually protective
MMP9 Q279R G allele was therefore associated with an increased
risk of scarring in the presence of IL10 risk alleles (IL10-1082C or
IL10-3575A minor alleles) and a decreased risk in the presence of
common IL10 (protective) alleles. Similar modelling at other loci
previously investigated in this cohort (IFN𝛾-1616, +3234; LTA -252,
+77; IkBL -63; IL-8 -251; GM-CSF2 27348, 27438) showed significant
or marginally significant evidence for two-way interactions, at the
genotype or allelic level, with the MMP9 Q279R SNP. Some of
these SNPs are in high LD and therefore not all the hypotheses
tested are independent. The existence both of LD between loci
and of potential biological interdependence between loci raises
methodological difficulties in correction for multiple testing. We
did not attempt any correction for multiple testing: and therefore
a contribution of chance to these results is difficult to exclude as we
point out in the main text. Comparing main and additional two-
way epistatic effects in the final model suggested that the inclusion
of interaction terms improved the fit of the model to the data, so
that the final best model included both main and epistatic effects.
For TS this model suggested that two-way interactions of MMP9-
Q279R with IFN𝛾-1616, IFN𝛾+3234, IL10-1082, IL8-251, LTA+77,
LTA-252, and IkBL-63 improved the fit of the model (data courtesy
of Natividad, Mabey, Holland, and Bailey).
This allele or haplotype is associated with higher levels of
IL10 transcription [73]. This may suggest that premature or
excessive downregulation ofMMP9 activity by IL-10 ultimately
increases risk. Each of these studies suffers from limited
sample size and large numbers of parallel statistical tests
under several different genetic models, whilst sometimes also
considering multiple phenotypes (i.e., scarring and trichia-
sis). Consequently the results should be interpreted in the
context of potential type I and type II errors.
The candidate gene approach has helped reinforce current
lines of investigation but has yet to resolve the paradigmof the
cellular versus immunological hypotheses or generate new
avenues of investigation into the basic biology of chlamydial
ocular disease. A genome-wide association scan (GWAS) is
an alternative to the candidate gene method and provides
an opportunity to generate new hypotheses in an unbiased
manner. GWAS requires much larger sample sizes than have
been previously described in trachoma and chlamydial uro-
genital disease and has its own limitations, particularly when
applied to samples from African populations [75]. There are
also relatively few GWAS in infectious disease [76]. TheWest
African malaria GWAS is perhaps a cautionary example [77].
The study showed that SNP markers in very close proximity
to the well-characterized causal SNP (rs334) of the “sickle-
cell trait” protective effect failed to reach genome-wide sig-
nificance, even though the study was well powered. This was
largely due to the low degree of linkage disequilibrium (LD)
between SNPs in African populations. The rs334 SNP, when
directly genotyped, was highly significant (𝑃 = 1.3 × 10−28),
whilst the bestmarker in theGWAS SNPs (𝑃 = 3.9×10−7) did
not reach genome-wide significance.The use of more densely
populated GWAS SNP arrays and imputation methods can
increase the likelihood of finding significant SNPs [78], but
imputation is essentially dependent on LD structures and
the imputation of rs334 in the malaria GWAS was far less
effective (𝑃 = 4.5×10−14) than direct genotyping of the locus
[77]. GWAS in African populations are less likely to directly
identify SNPs or alleles in association with disease than
equivalently sized studies in other populations.Therefore the
utility of a trachoma GWAS will most likely be in prioritizing
the best candidates and biologically plausible pathways. The
small effects of numerous polymorphisms in functionally
linked networks potentially have much greater contribution
to disease when tested en masse. Several groups are currently
pursuing genome-wide approaches to the understanding of
the host genetics of chlamydial diseases, either in human
clinical populations of pelvic inflammatory disease [79], tra-
choma [80], and advanced recombinant inbred mouse mod-
els [81] or in “cellular GWAS,” which uses in vitro infection
of extensively genotyped host cell lines [82, 83].The potential
power of a pathway-focus in genome-wide studies is evident
from the preliminary reports in trachoma [80] and a mouse
model system [81], both of which emphasize the importance
of G-protein coupled receptor signaling pathways in disease
processes relating to chlamydial infections.
4. Chlamydial Genomics and Pathogenesis
Initial single gene, multilocus sequence typing, and sub-
sequent whole genome sequencing (WGS) of chlamydial
species have provided insight into the processes involved in
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chlamydial pathogenesis. The first fully sequenced Chlamy-
dia trachomatis genome was a laboratory reference strain
(D/UW-3/Cx) passaged in the laboratory for more than 30
years after its initial isolation from a cervical swab in 1965.
The genome was completed by shotgun sequencing using
highly purified Ct genomic DNA obtained by bulk culture to
produce sufficient genomic DNA to generate the M13 linker-
adaptor library. More than 28,000 sequencing reactions
using dye-labeled primers and almost 4,700 dye-terminator
reactions were required to complete the genome [84]. Ten
to twelve years later, the first ocular chlamydial genomes
were fully sequenced prior to the wide scale introduction
of next generation sequencing (NGS) [85, 86]. Comparative
genomic analysis of these and subsequent chlamydial isolates
demonstrated overall similarity in gene content and order
across biovars and between chlamydial species [87–90]. This
high level synteny is correlatedwith the extent of evolutionary
divergence [90]. Application of NGS technologies has rapidly
advanced and expanded our understanding of chlamydial
comparative and evolutionary dynamics. RecentWGS analy-
sis demonstrated that there is extensive recombinationwithin
and between biovars [91] (also noted in other studies [92, 93])
and that there is evidence for genetic exchange and recombi-
nation within the cryptic plasmid [91]. This has challenged
our knowledge of chlamydial diversity and highlighted the
implications of recombination in pathogenesis. Other signifi-
cant advances including genetic manipulation of Chlamydiae
[94, 95], mutagenesis studies [95–98], and axenic culture [99]
facilitate the study of chlamydial metabolism and physiology
in the context of genetic studies. Novel presequencing enrich-
ment techniques such as immunomagnetic separation and
DNA-baiting techniques (SureSelect) have removed techni-
cal barriers to obtaining WGS data directly from clinical
specimens [100, 101]. Moreover, the ability to obtain WGS
data directly from clinical samples without the need for
culture obviates the problem of in vitro propagation and
subsequent loss of genomic diversity reflecting differences
between in vitro and in vivo evolutionary environments,
as has been demonstrated in Ct [102–104] and herpesvirus
species (Varicella Zoster Virus and Cytomegalovirus) [105,
106]. This allows the study of genetic variants associated
with disease, including those under positive selective pressure
through interaction with the host. Direct and targeted deep
resequencing has also enabled discovery of mixed infections
within seed stocks of cultures and from clinical isolates
[104, 107]. Putative virulence factors identified throughWGS
analysis and in vitro and animal studies include the poly-
morphic outer membrane protein family (Pmps) [84, 108–
110], type three secretion system (T3SS) and effectors [111–
113], genes involved in tryptophan [114–116] and glycogen
[94, 117] biosynthesis, members of the incA [118, 119] and
phospholipase-D [120, 121] families, genes from the heat
shock protein family [122, 123], the chlamydial cytotoxin
[124], and plasmid-encoded genes implicated in the regula-
tion of chromosomal virulence factors [97, 125, 126].
Pmps appear to fulfill several biological functions, but
the full extent of their role is not entirely clear. These
exported bacterial proteins have been shown to function
as autotransporters within the chlamydial outer membrane
[127–129]. Several chlamydial Pmps have been detected on
the chlamydial elementary body surface [127]. Some are
strongly immunogenic and elicit a proinflammatory response
[127].Theymay play a role in virulence regardingmodulation
of inflammation and adherence to and invasion of host cells
[129].
The chlamydial plasticity zone (PZ) is the site of extensive
genomic variation between the chlamydial serovars [88, 90].
The PZ contains a toxin whose function is thought to involve
GTPase inactivation and guanylate binding protein neutral-
ization resulting in interferon gamma (IFN𝛾) resistance [124,
130, 131]. IFN𝛾 stimulation of cells in vitro and in vivo induces
transcription of genes that cooperate to eliminate intracellu-
lar bacteria, suggesting that inhibition of thismechanismmay
contribute to the pathogenesis of chlamydial disease [131].
The genomic organisation of the cytotoxin varies such that
oculogenital strains have a single gene with a large deletion
and lymphogranuloma venereum (LGV) strains lack the gene
entirely, whilst the closely related C. muridarum (Cm) has
three intact copies [132, 133].Thismost likely reflects the IFN𝛾
evasionmechanism employed byCm in themouse compared
with that employed by urogenital strains in humans [133].
Since ocular strains lack a functional trp operon and only
have a partial toxin, how they evade IFN𝛾 is not fully
understood. The membrane attack complex/perforin protein
(CT153) and members of the phospholipase-D (PLD) family
are also encoded within the PZ [90].The PZ PLDs are present
in Ct [120] and other Chlamydiaceae [87, 134, 135]. These
proteins are known to modify lipids and membranes and
may be secreted and localize to the inclusion membrane
[121]. Reactivation of Ct from an IFN𝛾-induced persistent
state is blocked by primary alcohols (potent PLD inhibitors),
implying a role for PZ PLDs in this process [136].
Genomic analysis has shown that many Inc proteins
are produced by each chlamydial species and several are
produced early in development. Inc proteins, which are
T3SS effector proteins, may be important antigens in cell-
mediated immune responses following infection. IncA has
been defined as an effector protein proposed to mediate
inclusion fusion in Ct [118, 119]. IncA proteins exhibit an
innate ability to form vesicles and enter the membrane of
intracellular compartments [137]. A recent study of the Inc-
human “interactome” using affinity-purification mass spec-
trometry identified that 38/58 Incs interacted with human
proteins [138]. Many of the host targets were also targeted by
viral proteins implying conserved mechanisms of intracellu-
lar pathogenesis. IncE bound to components of the retromer,
which restricted chlamydial growth [138].
Work on the chlamydial T3SS [112] in combination with
the advent of WGS demonstrated that a family of chlamydial
proteins that localize to the inclusion membrane during
intracellular growth were a candidate T3SS [111]. This system
is important in bacterial pathogenesis and is essential for
virulence of a number of bacterial species [139]. In most of
these pathogens, the structural and effector genes are located
on distinct pathogenicity islands [140]. In Chlamydiae, these
genes are scattered across a number of operons and use a
sigma factor for constitutive gene expression, suggesting that
additional activators or repressors are required if components
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of the T3SS are developmentally regulated [113]. Given the
intracellular existence of Chlamydiae, these T3 secreted
products are likely to be important in pathogenesis.
The chlamydial plasmid has been shown to function as
a virulence factor in animal models [49, 141]. Phenotypic
differences vary betweenplasmid-cured andwild-type strains
with respect to infectivity, glycogen accumulation, induction
of inflammation, and activation of toll-like receptor pathways
[117, 142]. Plasmid deletion mutagenesis studies showed that
deletion of the plasmid-encoded pgp4 gene results in an in
vitro phenotype identical to that of a plasmid-free strain [97].
Bacterial transcriptome analysis found a decrease in tran-
script levels of a subset of chromosomal genes in a naturally
occurring plasmid-free strain of Ct, demonstrating that the
plasmid is a transcriptional regulator of virulence-associated
genes [125]. Maintenance of the plasmid at the relatively
low copy number of 5-6 plasmids per genome [143] carries
inherent risk of plasmid-loss during cell partition [144],
but naturally occurring plasmid-free strains are rare [145–
147]. This suggests that 5-6 plasmid copies may maximize
infectivity or intracellular survival whilst provoking minimal
host immune response. Recent host transcriptome studies
suggest that the plasmid may stimulate host cell expression
of PD-L1, which induces programmed cell death in immune
effector cells [48, 148].The plasmid is clearly strongly selected
for during successful infection or transmission [142] and
recent studies have shown that a plasmid-cured Ct strain is
less virulent in ocular infection ofmacaques and can function
as a live attenuated vaccine [49].
The ability to obtainWGS data directly from clinical sam-
ples enables a genome-wide approach to investigate associa-
tionswith disease phenotype and chlamydial load in naturally
occurring Ct infections. Pathogen GWAS studies are a pow-
erful tool to assess the association between a SNP or locus
and defined phenotypes. It has also been shown to be a robust
approach for discovering novel loci of interest in other bacte-
rial pathogens [149, 150]. A small number of bacterial GWAS
have revealed pathogen genetic associations with host adap-
tation in Campylobacter jejuni and Escherichia coli [151], drug
resistance in Mycobacterium tuberculosis [152], methicillin-
resistant Staphylococcus aureus (MRSA) [153], and Strepto-
coccus pneumoniae [154] and resulted in the identification of
virulence loci in methicillin-resistant Staphylococcus aureus
[149]. Rapid advances in WGS techniques will enhance our
understanding of chlamydial biology and diseases pathogen-
esis.
5. Bacterial Ecology of
the Conjunctiva and Trachoma
Persistent, severe inflammation is associated with conjuncti-
val scarring yet C. trachomatis is rarely detected in the eyes
of adults with disease signs [7]. This has led to the suggestion
that the inflammation seen in trachomatous disease is driven,
at least in part, by nonchlamydial pathogens and there is now
a growing evidence to support this hypothesis [155].
Studies carried out in The Gambia in the early 2000s
found that whilst viable bacteria, including Staphylococcus
aureus and Streptococcus species, could be cultured from
the eyes of healthy controls, bacterial infection was more
frequently identified in the eyes of cases with trachomatous
trichiasis [156]; Streptococcus pneumonia was the dominant
pathogen isolated. In trachoma endemic communities in
Tanzania, individuals with TS have been shown to be more
frequently infected with Streptococcus pneumoniae, Haemo-
philus influenzae, coagulase-negative Staphylococcus, and
Corynebacterium species than individuals with normal con-
junctivae [155]. Similar findings have been reported in
Ethiopians where comparison of the bacterial flora of con-
junctivae with trachomatous trichiasis versus trachoma-
tous scarring revealed increased frequency of isolation of
Streptococcus pneumoniae, Haemophilus influenzae, coagu-
lase-negative Staphylococcus, Corynebacterium, and viridans
streptococci species [157].
More recent studies have examined the presence of viable
bacteria in the eyes of children in regions of Tanzania and
The Gambia where there is a low prevalence of clinical
signs of active trachoma with correspondingly low levels of
ocular C. trachomatis infection. In both studies, children
with TF were more likely to have nonchlamydial bacteria in
their eyes, namely, Streptococcus pneumoniae orHaemophilus
influenzae, than children who had no clinical signs of disease
[158, 159]. In the Tanzanian studies, culture of these nonch-
lamydial bacterial infections was associated with increased
host conjunctival expression of IL17A, CXCL5, CCL18, and
KLRD1 [37]. Of these, IL17A, CXCL5, and CCL18 were also
associated with follicular and papillary inflammation.
The suggestion that nonchlamydial bacterial infection of
the eye contributes to the maintenance of an inflammatory
state that drives the scarring process is further supported by
immunological studies. In Tanzania, a study of individuals
with TS in the absence of TT found that nonchlamydial bac-
terial infection was associated with increased expression of
INDO, S100A7, DEFB4A, andMMP12 and decreased expres-
sion ofMMP10, SPARCL1, and CFH [38]. Clinical inflamma-
tion, which is consistently identified as a major risk factor for
progressive scarring, was associated with increased INDO,
IL1B, DEFB4A, CXCL5, MMP7, MMP9, MMP12, and CD83
and decreased MMP10, SPARCL1, and CFH. Data from lon-
gitudinal studies on recurrent trichiasis in The Gambia have
indicated that bacterial infection, particularly with Strepto-
coccus pneumonia, and clinical inflammation are associated
with recurrence following surgery [160]. Clinical inflamma-
tion and nonchlamydial bacteria were also associated with
increased expression of IL1B andMMP9 in this cohort [161].
The isolation, often at high loads, of bacteria such as
Streptococcus pneumoniae from the eyes of individuals with
trachoma may suggest that colonization exacerbates clinical
signs of the disease or, alternatively, that those with conjunc-
tival inflammation are more susceptible to colonization and
conjunctival scarring. Findings indicating increased numbers
of what are largely regarded as commensal bacteria (such
as coagulase-negative staphylococci and Corynebacterium
species) in trachomatous eyes are also of particular interest,
as alterations or dysbiosis of the microbiota could be a con-
tributing factor to disease.
The study of the “normal” or indigenous microbiota
that colonizes the human body has seen huge advances in
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the past decade with the application of NGS techniques
that enable the identification of viral, fungal, and bacterial
species. These methods have been particularly useful in the
identification of noncultivable bacteria directly from clinical
samples. These techniques have been perhaps best utilized
to describe the microbiota of the human gastrointestinal
tract and, in particular, changes in the microbiota associated
with inflammatory disease including inflammatory bowel
syndrome and Crohn’s disease. Biopsied intestinal tissue that
is inflamed tends to have reduced bacterial species diversity
and altered species composition as compared to tissue taken
from healthy controls [162–164]. The species composition of
the microbiota has also been found to play an important
role in the health of the epithelial barrier via induction and
maintenance of IL-17, IL-22, and regulatory T cells [165–167].
In the female genital tract, dysbiosis of the microbiota
(characterized by decreased numbers of lactobacilli and
polymicrobial overgrowth of anaerobic bacteria) is associated
with bacterial vaginosis. This and other alterations in the
vaginal microbiota are thought to be risk factors for reduced
fertility [168]. While the mechanism behind this is not yet
clear, bacterial vaginosis has been associated with elevated
cervical levels of IL-1𝛽 and IL-8, leading to the suggestion that
the induction of proinflammatory cytokines by the altered
vaginal microbiota is an unrecognized cause of infertility
[169].
At present, the metagenome of the ocular surface has not
been characterized and, to date, only a handful of studies
have applied NGS techniques, namely, deep-sequencing of
the 16S rRNA gene, to the characterization of the conjunctival
microbiota. A study of four healthy American volunteers
described a “core” conjunctival microbiota consisting of
Pseudomonas, Propionibacterium, Bradyrhizobium, Coryne-
bacterium, Acinetobacter, Brevundimonas, Staphylococcus,
Aquabacterium, Sphingomonas, and Streptococcus species
[170]. In contrast, the core members of the conjunctival
microbiota of a West African population were identified as
Corynebacterium, Streptococcus, Propionibacterium, Bacillus,
and Staphylococcus species [171, 172]. Amongst ophthalmolo-
gists and microbiologists, these results have been questioned
since the traditional view regards the ocular surface as a
sterile site of low biomass. This view is not confined to
those studying the ocular surface; there are many parallels
with those investigating the lung microbiome where there
was initial resistance to the concept that the lung was not a
“sterile” environment but in fact that healthy lung harbors a
complex community of bacteria [173].
Later studies on the conjunctival microbiota in Gambians
with trachoma used a case-control study design with and
without trachomatous disease (TF, TS, and TT) [172]. In
common with other pathologies of the mucosal epithelia,
this study found a disequilibrium of the normal flora, as
defined by the decreased richness (number of genera) and
diversity (number of genera and their abundance within the
community) associatedwith clinical signs of TS andTTwhen
compared with those with healthy eyes [172]. The decrease
in bacterial diversity seen in individuals with TS was largely
driven by an increase in Corynebacterium species in those
with trachomatous disease, which is consistent with earlier
studies characterizing the bacterial profile of the eye using
culture techniques. The ocular microbiota of children was
found to have greater richness and diversity in comparison
to that of adults. While few significant differences were
found in the microbiota of children with follicles versus
normal controls, the microbiota of one child with clinical
inflammation was dominated by Haemophilus species again
pointing to the potential role of nonchlamydial bacteria in
driving inflammation.
One drawback of the 16S rRNA gene sequencing
approach, particularly in low biomass samples such as con-
junctival swabs, is the potential for contamination from envi-
ronmental sources and the inability to distinguish between
viable and nonviable bacteria. Low biomass samples also
currently preclude WGS approaches that would facilitate
more a complete characterisation of the bacterial species and
the full metagenome (archaea, fungi, and viruses). Using
16S-amplicon sequencing, it is difficult to distinguish those
bacteria that actively colonize the conjunctival surface from
those that are transiently introduced into this niche [172].
Primer-bias, which can lead to misrepresentation in the
population [174], and bias introduced by sequencing depth,
which limits the ability to characterise those bacteria that
comprise the minority of the population [175], are also
limitations of the 16S sequencing approach. As a result,
there have been attempts to develop methods that might
distinguish viable from nonviable bacteria before entry into
the sequencing pipeline, such as the introduction of a DNase
I predigestion [176], or the use of community transcriptomics
to identify expressed bacterial components.
Culturomics is a relatively new field that couples high-
throughput culture with matrix-assisted laser desorption
ionization time-of-flight mass spectrometry (MALDI-TOF
MS) identification and is a technique that may provide
further means of addressing some of these issues. Studies of
the gut microbiota have developed culturomics to identify
bacterial species never before associated with the human
gastrointestinal tract as well as novel species not previously
described [177, 178]. As this technique targets viable cells, it is
less prone to artefacts resulting from bacterial DNA contami-
nation.The technique has also been used to establish cell-free
Chlamydia trachomatis culture, using radiolabelled amino
acids to demonstrate metabolic activity [99]. Culturomics
therefore offers the potential to close the gap between 16S-
amplicon sequencing and traditional microbiological culture
[177, 179].
New applications of NGS continue to evolve in infectious
disease immunology and the study of the role of the micro-
biota and specific microorganisms. One such technique is
IgA-SEQ, amethod that utilizes flow cytometry based sorting
to separate bacteria coated with IgA from noncoated bacteria
in a complex sample. The sorted fractions are then analysed
by 16S-amplicon sequencing to identify the bacteria. In two
recent studies, IgA-coated intestinal bacteria identified from
human volunteers suffering inflammatory bowel disease and
impaired gut-barrier function were cultured. These cultures
were then able to induce intestinal inflammation in germ-free
mice [180, 181]. These findings suggested that those bacteria
that are able to penetrate the mucin barrier are more likely
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to stimulate an immune inflammatory response. The IgA-
SEQmethod thereby provides an elegantmeans of identifying
and isolating those bacteria within the microbiota that drive
disease.
The application of sophisticated techniques to the study
of the conjunctival microbiota may offer better opportunities
to distinguish bacterial colonizers from bystanders as well
as identifying those bacteria that stimulate the immune
responses that drive inflammation and the scarring process.
The analysis of metagenomic data alongside host transcrip-
tome arrays may also aid in this search; unraveling the
interactions between the conjunctival microbiota and the
gene expression networks and pathways of inflammation that
lead to fibrosis is key to further understanding of microbiota-
host interactions in scarring disease.
6. Epigenetics and Chlamydial Infection
One possible explanation for the chronic inflammation and
continued presence of active disease signs in populations
once ocular Ct infection has been controlled is epigenetic
change of the host cell state. “Epigenetics” describes changes
in gene expression that are heritable through cell division,
without alteration to the DNA sequence itself. These changes
can be applied directly to DNA (CpG methylation), to the
proteins DNA is packaged around (chromatin modifications
such as histone methylation or acetylation), and to the
transcribed message (microRNA mediated silencing).
Bacteria and infection-induced inflammation are both
known to induce epigenetic changes in host cells, particularly
to genes in the MAPK, NFkB, and IFN𝛾 signaling pathways,
all of which are integral to the immune response (reviewed
in [182]). Helicobacter pylori induces genome-wide aberrant
hypermethylation of DNA in the gastric mucosa of pediatric
and adult samples [183]. In particular, methylation of E-
cadherin (and its downregulation, which is a characteristic of
epithelial-mesenchymal transition (EMT), discussed further
below) is induced byH. pylori infection via IL-1𝛽 stimulation
of NFkB, resulting in nitric oxide production and activa-
tion of DNA methyltransferases [184]. In a similar manner,
the Bacille Calmette-Guerin (BCG) vaccine induces long-
lasting and nonspecific increases in cytokine expression in
human monocytes via NOD2-dependent histone methyla-
tion of H2K4me3 [185]. Chlamydia encode SET (suppressor
of variegation-enhancer of zeste-trithorax) domain proteins,
which function as methyltransferases [186]. Ct encodes
nuclear effector (NUE), a SET domain histone methyltrans-
ferase which is secreted through the T3SS and shows activity
toward histones H2B, H3, and H4 in the host cell nucleus
[187]. As of yet, the targets and function of NUE in the host
remain to be identified. Humphrys and colleagues found that
a number of host genes encoding histones were differentially
expressed at 1 hour after infection, perhaps reflecting an
early modulatory effect of Ct infection on the host epigenetic
profile [188]. It is tempting to speculate that Ct stimulation of
pathogen recognition receptors may induce CpG or histone
methylation changes, or in fact that Ct may directly induce
host histone changes via NUE, causing an abnormal state of
chronic inflammation in the conjunctival epithelium.
7. The Role of Small RNAs in
Chlamydial Disease
Only 20% of transcription across the human genome is
associated with protein-coding genes [189] and it has become
clear that many of the non-protein-coding RNA species
that are transcribed have important regulatory roles. These
noncoding RNA species include microRNA (miRNA), short
interfering RNA (siRNA), piwi-interacting RNA (piRNA),
small nucleolar RNAs (snoRNA), other small RNAs, and long
noncoding RNA (lncRNA (>200 nucleotides)).
miRNA encoding sequences make up only around 2% of
the human genome but are estimated to regulate >60% of
protein-coding genes [190]. miRNA (miR) are short (18–22
nucleotides) single stranded sequences of RNA. miR regulate
gene expression through binding to complementary messen-
ger RNA (mRNA) sequences in the cytosol in association
with Argonaute proteins, forming a RNA-induced silencing
complex (RISC), leading to inhibition or degradation of
the target mRNA [191]. The “seed sequence” of the miR,
nucleotides 2–7 from the five prime ends, guides target
selection [192]. Half of knownmiR are found in polycistronic
units and are expressed in parallel, often sharing structure
and function [193, 194]. Due to flexibility in binding comple-
mentarity, an individual miR can target hundreds of different
genes and a gene might be targeted by many different miR
[194], forming a complex network of regulation. Abnormal
expression of miR may occur by the same factors regulating
expression of any gene, including epigenetic control of pre-
miR transcription or SNPs in the miR coding sequence. miR
expression can also be regulated at the posttranscriptional
level (as pre-miR or mature miR), by RNA-binding proteins
or by circular RNAs that can act as “sponges” [195–198].
Due to the far-reaching and complex roles of miR, a small
change in expression can have a profound effect on tissue
homeostasis.
miR are an important part of the host response to bacte-
ria, both pathogenic and commensal. Inflammation must be
tightly regulated; excess can lead to organ damage whereas
insufficient inflammation may facilitate the dissemination
of infection. Several miR are well characterized as having
important roles in the immune response against bacteria
(reviewed in [199–201]). miR-146 and miR-155 are upregu-
lated in immune cells following infection with a range of
bacteria, including Helicobacter pylori, Salmonella enterica,
Listeria monocytogenes, Francisella tularensis, and Mycobac-
terium species. Both miR-155 and miR-146 function in
negative feedback loops to prevent excessive inflammation
by silencing targets in the TLR4 signalling pathway. miR-
155 also maintains TNF expression and is essential for an
appropriate adaptive immune response. Distinct patterns of
miR expression are elicited by two strains of Cm that vary
in virulence in the murine genital tract [202]. miR-223-3p
and miR-18a-5p were induced in mice by both strains at 24
hours after infection. Interestingly, miR-155 expression was
increased in response to avirulent Cm but not in response
to the virulent strain of Cm. The failure to upregulate miR-
155 in the virulent infection could indicate an absence of the
negative feedback loop that is required to prevent excessive
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inflammation, leading to the increased pathology that was
observed. Gupta and colleagues investigated miR expression
following Cm infection in the murine genital model at a
later time point. At 6 days after bacterial challenge, miR-
125b-5p,miR-135a,miR-16,miR-214,miR-30c,miR-30e,miR-
182, miR-183, and miR-23b were downregulated in the lower
genital tract and miR-146 and miR-451 were upregulated
[203]. These changes were not maintained at 12 days after
infection. Knockdown of miR-125b-5p, miR-30c, and miR-
182 led to a failure to control Cm infection and, in CD4−/−
mice, levels of miR-125b-5p, miR-182, miR-183, and miR-135
were upregulated relative to wild-type infected mice. miR-
125b maintains the naivety of T cells and is downregulated
upon their differentiation and maturation [204]. miR-125b
also targets TNF and is thought to maintain the inactivity
of macrophages in the absence of bacterial TLR stimulation
[199]. miR-125b downregulation may therefore be required
for an appropriate immune response. Igietseme and col-
leagues have shown that, upon urogenital infection of mice
with a virulent LGV Ct strain (L2), murine miR-21, miR-
103, miR-107, let-7i, and miR-92b were downregulated in the
oviducts, though the time point at which these changes in
expression are observed is unclear [205].
Overexpression of miR-146a in psoriatic skin lesions
has been linked to a SNP in the miR-146 gene in a large
cohort of Chinese patients [206].Wang and colleagues looked
at the association of polymorphisms in miR-146a and the
NRLP3 inflammasome in association with susceptibility and
severity of urogenital Ct infection in two cohorts of Dutch
and Finnish women [207]. A SNP in NLRP3 was found to
associate with lower abdominal pain in Ct positive women;
however, no link with miR-146a was found. Our previous
work has identified that miR-147b is upregulated in scarring
and inflammatory trachoma and miR-1285 is upregulated
in scarring and inflammation when compared to scarring
alone [208]. miR-147b acts in a similar manner to miR-
146a; it is induced by TLR signaling and prevents excessive
inflammation in murine macrophages [209] and is thought
to have a homologous role in humans [210].The upregulation
of miR-147b in diseased individuals could represent repeated
TLR stimulation, perhaps by an abnormal microbiome. miR-
1285 has conflicting roles in regulation of the cell cycle
[211, 212]. Abnormal regulation of inflammation and cell
cycle could drive the chronic inflammation and fibrotic
proliferation associated with trachomatous pathology.
Transcriptome arrays comparing gene expression at var-
ious stages of trachomatous disease have found that many
thousands of genes are differentially regulated [34, 36]. In
an attempt to reduce this complexity, we used a data mining
approach (MSigDB) and found miR that were enriched for
targets within lists of differentially regulated genes of four
trachoma transcriptomes (Table 1). Of interest are the miR
with known roles in the regulation of EMT, which we discuss
further below. A number of miR that have been identified as
differentially expressed in Ct and Cm infection are enriched
for targets in these datasets, particularly in the comparison
of active disease with Ct infection against controls, which
is closest biologically to these murine models. Many of the
miR were predicted to have roles regulating cell proliferation
and apoptosis. This could be reflective of Ct preventing host
cell apoptosis to maintain the intracellular niche or T cell
and fibroblast proliferation contributing to inflammation and
fibrosis; however, a drawback of using datamining techniques
is the relative abundance of cancer-related miR associations
and pathways that dominate the literature. Pathogens and
commensals express their own regulatory RNAs and it is
emerging that these can be translocated into host cells to
subvert or manipulate the response. Several DNA viruses
express miR that target viral and host mRNAs to enhance
their own success and some express virulence factors that
manipulate host miR levels (reviewed in [213, 214]).Mycobac-
terium tuberculosis secreted effector ESAT-6 downregulates
let-7f in macrophages, releasing expression of A20, which is a
negative feedback regulator of the NFkB pathway [215]. This
results in a reduction of inflammatory cytokine production
and increasedM. tuberculosis survival. miR from the parasitic
nematodes Heligmosomoides polygyrus and Litomosoides sig-
modontis have recently been found in the serum of mice and
in discrete parasite-secreted exosomes, resulting in systemic
immune regulation and suppression following uptake by host
cells [216]. Little is known about bacterial miR and their
ability to modulate host responses.Mycobacterium marinum
expresses a candidate miR (23 nt long) that can be bound by
host RISC and silence an mRNA target, though a functional
role has not yet been identified [217]. Ct does not appear to
express any authentic miR species in human cells, as defined
by association with RISC proteins and a length of 22 ± 2 nt
[217]. Ct does, however, encode a number of noncoding
RNAswith distinct expression patterns throughout the devel-
opmental cycle, one of which regulates the transcription of
a Ct gene [218, 219]. Some lncRNA encoding sequences are
located on the Ct plasmid, a known virulence factor [220].
No effect on chlamydial gene transcription was identified by
“knockout” of one of these plasmid-encoded miR, but an
effect on host transcription was not examined [97].
8. Epithelial-Mesenchymal Transition and
Chlamydial Disease
EMT is a reversible process by which epithelial cells differen-
tiate into mesenchymal cells. Currently 3 types of EMT are
recognised. In type-I EMT, epithelial cells differentiate into
mesenchymal cells to migrate around the growing embryo
during fetal development. These mesenchymal cells can then
transform back into epithelia through the reverse process of
mesenchymal-epithelial transition (MET) to establish new
distant sites of epithelial tissue. Type-II EMT is associated
with inflammation-induced tissue fibrosis and type-III EMT
occurs in cancer when epithelial tumors metastasize. It is
thought that the 3 types of EMT have similar stimuli, signal-
ing cascades, and regulation [221, 222]. Endothelial cells also
differentiate into mesenchymal cells when subjected to the
same stimuli (EndMT) and can contribute to cardiac fibrosis
[223].
Type-II EMT (EMT-2) occurs in response to inflam-
mation and can lead to loss of organ function through
pathological fibrosis. Inflammatory cytokines, growth fac-
tors, and MMPs activate a chain of transcription factors that
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Table 1: miR predicted to regulate differentially expressed transcripts from four array datasets.
miR functional categories
MsigDb predicted miR based on differentially regulated mRNA transcripts
(FC > 1.5 Adj. 𝑃 < 0.01) from 4 trachoma transcriptomes
Active disease with Ct
infection
(GSE20436)
Active disease
(GSE20430)
Trachomatous scarring
disease with
inflammation
(GSE24383)
Trachomatous trichiasis
with inflammation
(GSE23705)
Inflammation/infection
let-7 family [205] miR-511 let-7 family [205]
miR-125a/b [203] miR-19a/b
miR-19a/b miR-224
miR-29a/b/c
EMT/fibrosis
miR-200b/c, miR-429 miR-200b/c, miR-429
miR-506 miR-29a/b/c
miR-506
miR-520d
Cell cycle/cancer
let-7 family [205] miR-518a-2 miR-128a/b let-7 family[205]
miR-124a miR-186 miR-21[202, 205] miR-19a/b
miR-125a/b [203] miR-130a/b, miR-301 miR-26a/b miR-22
miR-15 family miR-519a/b/c miR-224
miR-17-5p, miR-20a/b,
miR-106a/b, and miR-519d
miR-25, miR-32,
miR-92, miR-363, and
miR-367 [205]
miR-19a/b miR-516-3p
miR-218 miR-519a/b/c
miR-23a/b [203] miR-520d
miR-30a/b/c/d/e-5p [203]
miR-519a/b/c
miR-524
miR-9
Other miR-130a/b, miR-301 miR-153 miR-27a/b
miR-516-5p
Phenotype comparisons are as follows: normal healthy (N) children aged 1–9 versus those with active trachoma (TF) and Ct infection (GSE20436); children
aged 1–9 with TF (with or without Ct infection) versus N (GSE20430); N adults versus adults with trachomatous scarring and clinical inflammation (TSI)
(GSE24383); andN adults versus adults with trichiasis and clinical inflammation (TTI) (GSE23705). EnrichedmiR are grouped into functional categories based
on well-characterized roles in the literature. References show published studies that identify miR in bold as differentially expressed in chlamydial infection.
cause downregulation of epithelial characteristics in cells and
gain of mesenchymal properties. The basement membrane is
degraded by MMPs, allowing differentiating cells to migrate
into the interstitial tissue [224]. New mesenchymal cells can
then acquire a myofibroblast phenotype [225], secreting col-
lagen 1 and expressing 𝛼-smooth muscle actin and therefore
contributing to extracellular matrix deposition and “wound”
contraction. EMT-2 is known to contribute to the pathology
of many fibrotic diseases, including kidney fibrosis [225],
idiopathic pulmonary fibrosis [226], and cardiac and liver
fibrosis [223, 227]. In a murine model of liver fibrosis, up
to 45% of fibroblasts were found to have originated from
hepatocytes [227]. Evidence of EMT has been shown both in
acute wound healing and in chronic fibrotic (hypertrophic)
scars where there is also evidence of unresolved inflamma-
tion [228]. EMT-2 ceases when inflammatory stimuli stop;
therefore it appears that EMT-2 only become pathological
in an environment of chronic inflammation. Having said
that, EMT cells can be resistant to apoptosis (reviewed in
[229]), possibly arising from the need for resilient cells to
seed new sites of epithelial tissue in embryonic development.
In addition to resisting apoptosis, EMT cells can acquire
stem-cell-like properties allowing self-renewal [230–232], a
property which is known to play a role in various cancers
and which could contribute to the chronic fibrosis that is
observed in trachoma. EMT-activating transcription factor
ZEB1 represses expression of the stemness-inhibiting miR-
200 family, therefore releasing expression of stem-cell factors
and leading to EMT and self-renewal. From the evidence of
our in silico analysis (Table 1), we suggest that the miR-200
family may be associated with trachoma.
Epigenetic changes can fix the expression of genes that
induce EMT, contributing to chronic fibrosis and can-
cer. TGF𝛽-induced EMT is associated with global loss of
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heterochromatin mark H3K9Me2 and gain of euchromatin
marks H3K4Me3 and H3K36Me3 [233]. In cancer-related
EMT, hypermethylation of E-cadherin is found [234, 235].
SNAIL, a transcription factor associated with EMT, is
thought to contribute to this effect by recruiting DNA
methyltransferase-1 to the E-cadherin promoter [236] and
has been shown to modify the chromatin structure at the
site through recruitment of the Sin3A/histone deacetylase 1
(HDAC1)/HDAC2 complex [237].
Primary hepatocytes infected with hepatitis C virus
in vitro have been shown to upregulate biomarkers of
EMT [238]. LPS-treated intrahepatic biliary epithelial cells
upregulate TGF𝛽1 in vitro and stimulate EMT through
the TGF𝛽1/SMAD2/3 pathway [239]. EMT-2 has also been
observed during herpes virus infection in vitro and in vivo
and following E. coli infection in vitro [240, 241].Helicobacter
pylori virulence factors VacA and CagA disrupt epithelial
cell tight junctions and polarity [242–244] and upregulation
of EMT transcription factors and biomarkers in gastric cell
lines requires both the cag pathogenicity island and NFkB
activation [245, 246]. EMT can thus be stimulated indirectly
through inflammatory signals or directly by pathogens. Ct
infected epithelial cells in ex vivo fallopian tube tissue show
phenotypic changes characteristic of EMT, such as decreased
polarity and cell adhesion [247]. The WNT pathway was
upregulated and 𝛽-catenin was recruited to the chlamydial
inclusion. Loss of epithelial cell-cell adhesion, N-cadherin/𝛽-
catenin complex formation, and recruitment of 𝛽-catenin to
the chlamydial inclusion have also been observed in vitro
[248]. Nectin-1, an integral molecule of epithelial cell tight
junctions and adherens junctions, was downregulated at the
posttranscriptional level by 85% in Ct infected HeLa cells,
which was dependent on live infection [249]. Disruptions
to key components of the WNT and Notch signaling path-
ways, intercellular junctions and adhesion, and cytoskeletal
remodeling have been identified by RNA-sequencing as early
as one hour after infection of HeLa cells with serovar E [188].
Transcriptomic profiling of TT and subsequent gene-set
enrichment analysis has also shown significant enrichment
in members of the WNT pathway [36, 250]. These data
therefore support a role for WNT signaling in both active
infection and later stages of chlamydial disease. Given that
WNT signaling stimulates EMT in vitro [251] and the Akt/𝛽-
catenin pathway mediates EMT activation following HCV
and H. pylori infection [238, 244], it is therefore tempting
to speculate that Ct induces EMT-2 in the conjunctival
epithelium, either directly or via Ct-induced inflammation.
9. Conclusions
The development of scarring trachoma represents a complex
multigenic system where each host factor contributes a small
protective or deleterious risk. Interaction of each of these
factors adds a further layer of complexity to understanding of
the disease process. Outside of host genetic factors, balance
or dysbiosis of the ocular surface microbiome coupled to
Ct genetic variation and environmental risk factors each
contributes to amultilayered disease network that determines
protection or pathology. Excessive or uncontrolled prolonged
inflammation is the main risk factor for pathology. Genes
and pathways that are dysregulated in inflammation, infec-
tion, and scarring have been identified, but clear causative
links between inflammation and scarring remain elusive.
To address this, we need in vitro studies and longitudinal
clinical studies of infection, inflammation, and progressive
scarring in childhood when scarring evolves. Unlike human
sexually transmitted chlamydial infections, studies such as
these are still possible in trachoma endemic populations.
The current trend [252, 253] and emerging toolkit [254–
263] for using a systems-wide or systems biology analysis of
data promise to look beyond single markers towards entire
molecular and cellular pathways across multiple layers of
disease. The ultimate goal of the systems approaches should
be to define a model that integrates data from these multiple
layers including the host genetic background, composition
of the microbiome, host response (transcriptome, proteome,
and epigenome), and pathogen variation [188, 264] in order
to explain the route to scarring or protection.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] Sightsavers, “Sightsavers Annual Review: 24,” MISC12, 2012.
[2] WHO Alliance, “Weekly epidemiologicalrecord,” Releve´ e´pide´-
miologique Hebdomadaire, vol. 96, pp. 421–428, 2014.
[3] J. D. Keenan, B. Ayele, T. Gebre et al., “Childhood mortality in
a cohort treated with mass azithromycin for trachoma,” Clinical
Infectious Diseases, vol. 52, no. 7, pp. 883–888, 2011.
[4] E. J. Giamarellos-Bourboulis, “Macrolides beyond the conven-
tional antimicrobials: a class of potent immunomodulators,”
International Journal of Antimicrobial Agents, vol. 31, no. 1, pp.
12–20, 2008.
[5] V. Jimenez, H. C. Gelderblom, R. Mann Flueckiger, P. M. Emer-
son, D. Haddad, and T. M. Lietman, “Mass drug administration
for trachoma: how long is not long enough?” PLoS Neglected
Tropical Diseases, vol. 9, no. 3, Article ID e0003610, 2015.
[6] C. L. Coles, K.Mabula, J. C. Seidman et al., “Mass distribution of
azithromycin for trachoma control is associated with increased
risk of azithromycin-resistant Streptococcus pneumoniae car-
riage in young children 6 months after treatment,” Clinical
Infectious Diseases, vol. 56, no. 11, pp. 1519–1526, 2013.
[7] M. J. Burton, S. N. Rajak, V. H. Hu et al., “Pathogenesis of pro-
gressive scarring trachoma in Ethiopia and Tanzania and its
implications for disease control: two cohort studies,” PLoS
Neglected Tropical Diseases, vol. 9, no. 5, Article ID e0003763,
2015.
[8] R. G. Rank and L. Yeruva, “Hidden in plain sight: chlamydial
gastrointestinal infection and its relevance to persistence in
human genital infection,” Infection and Immunity, vol. 82, no.
4, pp. 1362–1371, 2014.
[9] A. P. Craig, F. Y. S. Kong, L. Yeruva et al., “Is it time to switch to
doxycycline from azithromycin for treating genital chlamydial
infections in women? Modelling the impact of autoinoculation
from the gastrointestinal tract to the genital tract,” BMC
Infectious Diseases, vol. 15, article 200, 2015.
14 Mediators of Inflammation
[10] A. R. Last, S. E. Burr, H. A. Weiss et al., “Risk factors for
active trachoma and ocular Chlamydia trachomatis infection in
treatment-na¨ıve trachoma-hyperendemic communities of the
Bijago´s Archipelago, Guinea Bissau,” PLoS Neglected Tropical
Diseases, vol. 8, no. 6, Article ID e2900, 2014.
[11] V. H. Hu, P. Massae, H. A. Weiss et al., “In vivo confocal micro-
scopy of trachoma in relation to normal tarsal conjunctiva,”
Ophthalmology, vol. 118, no. 4, pp. 747–754, 2011.
[12] V.H.Hu,M. J. Holland, I. A. Cree et al., “In vivo confocalmicro-
scopy and histopathology of the conjunctiva in trachomatous
scarring and normal tissue: a systematic comparison,” British
Journal of Ophthalmology, vol. 97, no. 10, pp. 1333–1337, 2013.
[13] D. C. W. Mabey, V. Hu, R. L. Bailey, M. J. Burton, andM. J. Hol-
land, “Towards a safe and effective chlamydial vaccine: lessons
from the eye,” Vaccine, vol. 32, no. 14, pp. 1572–1578, 2014.
[14] S. Sowa, J. Sowa, L. H. Collier, andW. A. Blyth, “Trachoma vac-
cine field trials in The Gambia,” Journal of Hygiene, vol. 67, no.
4, pp. 699–717, 1969.
[15] R. L. Bailey, M. J. Burton, and D. C. W. Mabey, “Trachoma
vaccine trials in the Gambia,” in Chlamydial Infections. Pro-
ceedings of the Thirteenth International Symposium on Human
Chlamydial Infections, J. Schachter, G. Byrne, and M. A. Cher-
nesky, Eds., pp. 485–488,AsilomarConferenceGrounds, Pacific
Grove, Calif, USA, 2014.
[16] D. C.W.Mabey, V. H. Hu, R. L. Bailey et al., “Towards a safe and
effective chlamydial vaccine: lessons from the eye,” in Proceed-
ings of the 13th International Symposium on Human Chlamy-
dial Infections, J. Schachter, G. Byrne, M. A. Chernesky, and
etal, Eds., pp. 489–492, Asilomar Conference Grounds, Pacific
Grove, Calif, USA, June 2014.
[17] V.H.Hu,M. J.Holland, andM. J. Burton, “Trachoma: protective
and pathogenic ocular immune responses to Chlamydia tra-
chomatis,” PLoS Neglected Tropical Diseases, vol. 7, no. 2, Article
ID e2020, 2013.
[18] R. G. Rank, C. Dascher, A. K. Bowlin, and P. M. Bavoil, “Sys-
temic immunization with Hsp60 alters the development of
chlamydial ocular disease,” Investigative Ophthalmology and
Visual Science, vol. 36, no. 7, pp. 1344–1351, 1995.
[19] E.A.Wagar, J. Schachter, P. Bavoil, andR. S. Stephens, “Differen-
tial human serologic response to two 60,000 molecular weight
Chlamydia trachomatis antigens,” Journal of Infectious Diseases,
vol. 162, no. 4, pp. 922–927, 1990.
[20] T. Skwor, R. P. Kandel, S. Basravi, A. Khan, B. Sharma, and
D. Dean, “Characterization of humoral immune responses to
chlamydial HSP60, CPAF, and CT795 in inflammatory and
severe trachoma,” Investigative Ophthalmology &Visual Science,
vol. 51, no. 10, pp. 5128–5136, 2010.
[21] N. M. Budrys, S. Gong, A. K. Rodgers et al., “Chlamydia
trachomatis antigens recognized in women with tubal factor
infertility, normal fertility, and acute infection,” Obstetrics and
Gynecology, vol. 119, no. 5, pp. 1009–1016, 2012.
[22] C. Lu,M. J.Holland, S.Gong et al., “Genome-wide identification
of Chlamydia trachomatis antigens associated with trachoma-
tous trichiasis,” Investigative Ophthalmology & Visual Science,
vol. 53, no. 6, pp. 2551–2559, 2012.
[23] M. J. Holland, R. L. Bailey, L. J. Hayes, H. C. Whittle, and D.
C. W. Mabey, “Conjunctival scarring in trachoma is associated
with depressed cell-mediated immune responses to chlamydial
antigens,” Journal of Infectious Diseases, vol. 168, no. 6, pp. 1528–
1531, 1993.
[24] M. J. Holland, R. L. Bailey, D. J. Conway et al., “T helper type-
1 (Th1)/Th2 profiles of peripheral blood mononuclear cells
(PBMC); responses to antigens of Chlamydia trachomatis in
subjects with severe trachomatous scarring,” Clinical & Experi-
mental Immunology, vol. 105, pp. 429–435, 1996.
[25] A. M. Abu El-Asrar, K. Geboes, K. F. Tabbara, S. A. Al-Khar-
ashi, L. Missotten, and V. Desmet, “Immunopathogenesis of
conjunctival scarring in trachoma,” Eye, vol. 12, no. 3, pp. 453–
460, 1998.
[26] A. Gall, A. Horowitz, H. Joof et al., “Systemic effector and regu-
latory immune responses to chlamydial antigens in trachoma-
tous trichiasis,” Frontiers in Microbiology, vol. 2, article 10, 2011.
[27] R. C. Brunham and J. Rey-Ladino, “Immunology of Chlamydia
infection: implications for a Chlamydia trachomatis vaccine,”
Nature Reviews Immunology, vol. 5, no. 2, pp. 149–161, 2005.
[28] N.Olivares-Zavaleta,W.M.Whitmire, L. Kari, G. L. Sturdevant,
and H. D. Caldwell, “CD8+ T cells define an unexpected role in
live-attenuated vaccine protective immunity against Chlamydia
trachomatis infection inmacaques,”The Journal of Immunology,
vol. 192, no. 10, pp. 4648–4654, 2014.
[29] R. S. Stephens, “The cellular paradigm of chlamydial pathogen-
esis,” Trends in Microbiology, vol. 11, no. 1, pp. 44–51, 2003.
[30] S. J. Rasmussen, L. Eckmann, A. J. Quayle et al., “Secretion
of proinflammatory cytokines by epithelial cells in response to
Chlamydia infection suggests a central role for epithelial cells in
chlamydial pathogenesis,” The Journal of Clinical Investigation,
vol. 99, no. 1, pp. 77–87, 1997.
[31] S. Dessus-Babus, T. L. Darville, F. P. Cuozzo, K. Ferguson, and P.
B. Wyrick, “Differences in innate immune responses (in vitro)
to HeLa cells infected with nondisseminating serovar E and
disseminating serovar L2 of Chlamydia trachomatis,” Infection
and Immunity, vol. 70, no. 6, pp. 3234–3248, 2002.
[32] Z. Zhu, C. G. Lee, T. Zheng et al., “Airway inflammation and
remodeling in asthma. Lessons from interleukin 11 and inter-
leukin 13 transgenic mice,” American Journal of Respiratory and
Critical Care Medicine, vol. 164, no. 10, pp. S67–S70, 2001.
[33] L. R. Buckner, M. E. Lewis, S. J. Greene, T. P. Foster, and A. J.
Quayle, “Chlamydia trachomatis infection results in a modest
pro-inflammatory cytokine response and a decrease in T cell
chemokine secretion in human polarized endocervical epithe-
lial cells,” Cytokine, vol. 63, no. 2, pp. 151–165, 2013.
[34] A. Natividad, T. C. Freeman, D. Jeffries et al., “Human conjunc-
tival transcriptome analysis reveals the prominence of innate
defense in Chlamydia trachomatis infection,” Infection and
Immunity, vol. 78, no. 11, pp. 4895–4911, 2010.
[35] A. L. Barron, Microbiology of Chlamydia, edited by: A. L.
Barron, CRC Press, 1988.
[36] M. J. Burton, S. N. Rajak, J. Bauer et al., “Conjunctival transcrip-
tome in scarring trachoma,” Infection and Immunity, vol. 79, no.
1, pp. 499–511, 2011.
[37] M. J. Burton, A. Ramadhani, H. A.Weiss et al., “Active trachoma
is associated with increased conjunctival expression of IL17A
and profibrotic cytokines,” Infection and Immunity, vol. 79, no.
12, pp. 4977–4983, 2011.
[38] V. H. Hu, H. A.Weiss, A. M. Ramadhani et al., “Innate immune
responses and modified extracellular matrix regulation charac-
terize bacterial infection and cellular/connective tissue changes
in scarring trachoma,” Infection and Immunity, vol. 80, no. 1, pp.
121–130, 2012.
Mediators of Inflammation 15
[39] D. J. Conway, M. J. Holland, A. E. Campbell et al., “HLA
class I and II polymorphisms and trachomatous scarring in a
Chlamydia trachomatis—endemic population,” The Journal of
Infectious Diseases, vol. 174, no. 3, pp. 643–646, 1996.
[40] R. W. Peeling, R. L. Bailey, D. J. Comvay et al., “Antibody
response to the 60-kDa chlamydial heat-shock protein is associ-
ated with scarring trachoma,”The Journal of Infectious Diseases,
vol. 177, no. 1, pp. 256–259, 1998.
[41] L. K. Gaur, R. W. Peeling, M. Cheang et al., “Association of
Chlamydia trachomatis heat-shock protein 60 antibody and
HLA class II DQ alleles,” Journal of Infectious Diseases, vol. 180,
no. 1, pp. 234–237, 1999.
[42] C. R. Cohen, S. S. Sinei, E. A. Bukusi, J. J. Bwayo, K. K. Holmes,
and R. C. Brunham, “Human leukocyte antigen class II DQ
alleles associated with Chlamydia trachomatis tubal infertility,”
Obstetrics and Gynecology, vol. 95, no. 1, pp. 72–77, 2000.
[43] M. J. Holland, D. J. Conway, T. J. Blanchard et al., “Synthetic
peptides based on Chlamydia trachomatis antigens identify
cytotoxic T lymphocyte responses in subjects from a trachoma-
endemic population,”Clinical & Experimental Immunology, vol.
107, no. 1, pp. 44–49, 1997.
[44] O. S.M.Mahdi, H. C.Whittle, H. Joof, D. C.W.Mabey, and R. L.
Bailey, “Failure to detect HLA-A∗6802-restricted CD8+ T cells
specific for Chlamydia trachomatis antigens in subjects from
trachoma-endemic communities,” Clinical and Experimental
Immunology, vol. 123, no. 1, pp. 68–72, 2001.
[45] M. J. Holland,N. Faal, I. Sarr et al., “The frequency ofChlamydia
trachomatis major outer membrane protein-specific CD8+ T
lymphocytes in active trachoma is associated with current
ocular infection,” Infection and Immunity, vol. 74, no. 3, pp.
1565–1572, 2006.
[46] M. N. Starnbach, M. J. Bevan, and M. F. Lampe, “Protective
cytotoxic T lymphocytes are induced during murine infection
with Chlamydia trachomatis,” The Journal of Immunology, vol.
153, no. 11, pp. 5183–5189, 1994.
[47] S.-K. Kim, L. Devine, M. Angevine, R. DeMars, and P. B.
Kavathas, “Direct detection and magnetic isolation of Chlamy-
dia trachomatis major outer membrane protein-specific CD8+
CTLs with HLA class I tetramers,” Journal of Immunology, vol.
165, no. 12, pp. 7285–7292, 2000.
[48] S. C. Fankhauser and M. N. Starnbach, “PD-L1 limits the
mucosal CD8+ T cell response to Chlamydia trachomatis,” The
Journal of Immunology, vol. 192, no. 3, pp. 1079–1090, 2014.
[49] L. Kari, W. M. Whitmire, N. Olivares-Zavaleta et al., “A live-
attenuated chlamydial vaccine protects against trachoma in
nonhuman primates,” The Journal of Experimental Medicine,
vol. 208, no. 11, pp. 2217–2223, 2011.
[50] K. P. Karunakaran, H. Yu, X. Jiang et al., “Outer membrane
proteins preferentially loadMHC class II peptides: implications
for a Chlamydia trachomatis T cell vaccine,” Vaccine, vol. 33, no.
18, pp. 2159–2166, 2015.
[51] A. G.White, J. Bogh,W. Leheny et al., “HLA antigens inOmanis
with blinding trachoma: markers for disease susceptibility and
resistance,” British Journal of Ophthalmology, vol. 81, no. 6, pp.
431–434, 1997.
[52] M. Abbas, L. D. Bobo, Y.-H. Hsieh et al., “Human leukocyte
antigen (HLA)-B, DRB1, and DQB1 allotypes associated with
disease and protection of trachoma endemic villagers,” Inves-
tigative Ophthalmology and Visual Science, vol. 50, no. 4, pp.
1734–1738, 2009.
[53] C.H. Roberts, S.Molina, P.Makalo et al., “Conjunctival scarring
in trachoma is associated with the HLA-C Ligand of KIR and
is exacerbated by heterozygosity at KIR2DL2/KIR2DL3,” PLoS
Neglected Tropical Diseases, vol. 8, no. 3, Article ID e2744, 2014.
[54] C. C. Winter, J. E. Gumperz, P. Parham, E. O. Long, and N.
Wagtmann, “Direct binding and functional transfer of NK cell
inhibitory receptors reveal novel patterns of HLA-C allotype
recognition,”The Journal of Immunology, vol. 161, no. 2, pp. 571–
577, 1998.
[55] E. Ciccone, D. Pende, M. Vitale et al., “Self class I molecules
protect normal cells from lysis mediated by autologous natural
killer cells,” European Journal of Immunology, vol. 24, no. 4, pp.
1003–1006, 1994.
[56] M. Colonna, E. G. Brooks, M. Falco, G. B. Ferrara, and J. L.
Strominger, “Generation of allospecffic natural killer cells by
stimulation across a polymorphism of HLA-C,” Science, vol.
260, no. 5111, pp. 1121–1124, 1993.
[57] M. Colonna, G. Borsellino, M. Falco, G. B. Ferrara, and J. L.
Strominger, “HLA-C is the inhibitory ligand that determines
dominant resistance to lysis by NK1- and NK2-specific natural
killer cells,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 90, no. 24, pp. 12000–12004,
1993.
[58] R. Biassoni, C. Cantoni, M. Falco et al., “The human leukocyte
antigen (HLA)-C-specific ‘activatory’ or ‘inhibitory’ natural
killer cell receptors display highly homologous extracellular
domains but differ in their transmembrane and intracytoplas-
mic portions,” The Journal of Experimental Medicine, vol. 183,
no. 2, pp. 645–650, 1996.
[59] E. O. Long, M. Colonna, and L. L. Lanier, “Inhibitory MHC
class I receptors on NK and T cells: a standard nomenclature,”
Immunology Today, vol. 17, no. 2, article 100, 1996.
[60] M. Colonna and J. Samaridis, “Cloning of immunoglobulin-
superfamily members associated with HLA-C and HLA-B
recognition by human natural killer cells,” Science, vol. 268, no.
5209, pp. 405–408, 1995.
[61] S. Kim, J. Poursine-Laurent, S. M. Truscott et al., “Licensing
of natural killer cells by host major histocompatibility complex
class I molecules,” Nature, vol. 436, no. 7051, pp. 709–713, 2005.
[62] A. Moretta, C. Bottino, D. Pende et al., “Identification of
four subsets of human CD3−CD16+ natural killer (NK) cells
by the expression of clonally distributed functional surface
molecules: correlation between subset assignment of NK clones
and ability to mediate specific alloantigen recognition,” Journal
of Experimental Medicine, vol. 172, no. 6, pp. 1589–1598, 1990.
[63] A. Moretta, G. Tambussi, C. Bottino et al., “A novel surface
antigen expressed by a subset of human CD3−CD16+ natural
killer cells. Role in cell activation and regulation of cytolytic
function,”The Journal of Experimental Medicine, vol. 171, no. 3,
pp. 695–714, 1990.
[64] B. Huard and L. Karlsson, “A subpopulation of CD8+ T cells
specific for melanocyte differentiation antigens expresses killer
inhibitory receptors (KIR) in healthy donors: evidence for a role
of KIR in the control of peripheral tolerance,” European Journal
of Immunology, vol. 30, no. 6, pp. 1665–1675, 2000.
[65] S. Ferrini, A. Cambiaggi, R. Meazza et al., “T cell clones
expressing the natural killer cell-related p58 receptor molecule
display heterogeneity in phenotypic properties and p58 func-
tion,” European Journal of Immunology, vol. 24, no. 10, pp. 2294–
2298, 1994.
16 Mediators of Inflammation
[66] N.-K. S. Al Basatena, A. MacNamara, A. M. Vine et al.,
“KIR2DL2 enhances protective and detrimental HLA class I-
mediated immunity in chronic viral infection,” PLoS Pathogens,
vol. 7, no. 10, Article ID e1002270, 2011.
[67] W. K. Chan, P. Rujkijyanont, G. Neale et al., “Multiplex and
genome-wide analyses reveal distinctive properties of KIR+ and
CD56+ T cells in human blood,”The Journal of Immunology, vol.
191, no. 4, pp. 1625–1636, 2013.
[68] D. J. Conway, M. J. Holland, R. L. Bailey et al., “Scarring tra-
choma is associated with polymorphism in the tumor necrosis
factor alpha (TNF-𝛼) gene promoter and with elevated TNF-𝛼
levels in tear fluid,” Infection and Immunity, vol. 65, no. 3, pp.
1003–1006, 1997.
[69] A. Natividad, N. Hanchard, M. J. Holland et al., “Genetic vari-
ation at the TNF locus and the risk of severe sequelae of
ocular Chlamydia trachomatis infection in Gambians,” Genes &
Immunity, vol. 8, no. 4, pp. 288–295, 2007.
[70] B. Atik, T. A. Skwor, R. P. Kandel et al., “Identification of novel
single nucleotide polymorphisms in inflammatory genes as risk
factors associated with trachomatous trichiasis,” PLoSONE, vol.
3, no. 10, Article ID e3600, 2008.
[71] A. Natividad, J. Wilson, O. Koch et al., “Risk of trachomatous
scarring and trichiasis in Gambians varies with SNP haplotypes
at the interferon-gamma and interleukin-10 loci,” Genes and
Immunity, vol. 6, no. 4, pp. 332–340, 2005.
[72] A. Natividad, J. Hull, G. Luoni et al., “Innate immunity in ocular
Chlamydia trachomatis infection: contribution of IL8 and CSF2
gene variants to risk of trachomatous scarring in Gambians,”
BMCMedical Genetics, vol. 10, article 138, 2009.
[73] A. Natividad, M. J. Holland, K. A. Rockett et al., “Susceptibility
to sequelae of human ocular chlamydial infection associated
with allelic variation in IL10 cis-regulation,” Human Molecular
Genetics, vol. 17, no. 2, pp. 323–329, 2008.
[74] M. Savy, B. J. Hennig, C. P. Doherty et al., “Haptoglobin and
sickle cell polymorphisms and risk of active trachoma in
gambian children,” PLoS ONE, vol. 5, no. 6, Article ID e11075,
2010.
[75] Y.-Y. Teo, K. S. Small, and D. P. Kwiatkowski, “Methodological
challenges of genome-wide association analysis in Africa,”
Nature Reviews Genetics, vol. 11, no. 2, pp. 149–160, 2010.
[76] M. J. Newport and C. Finan, “Genome-wide association studies
and susceptibility to infectious diseases,” Briefings in Functional
Genomics, vol. 10, no. 2, pp. 98–107, 2011.
[77] M. Jallow, Y. Y. Teo, K. S. Small et al., “Genome-wide and
fine-resolution association analysis of malaria in West Africa,”
Nature Genetics, vol. 41, pp. 657–665, 2009.
[78] B. Howie, C. Fuchsberger, M. Stephens, J. Marchini, and G. R.
Abecasis, “Fast and accurate genotype imputation in genome-
wide association studies through pre-phasing,”Nature Genetics,
vol. 44, no. 8, pp. 955–959, 2012.
[79] SA. Morre´, S. Ouburg, V.-D. Margreet, S. Ioana, and F. Fabrizio,
“EpiGenChlamydia Consortium,” 2015, http://www.epigenchla-
mydia.eu/cms/.
[80] C. H. Roberts, C. Franklin, S. Molina-Gonzalez et al., “A
genome wide association scan reveals pathway—wide genomic
differences between cases of scarring trachoma and controls,”
in Proceedings of the 13th International Symposium on Human
Chlamydial Infections, J. Schachter, G. Byrne, M. A. Chernesky,
and etal, Eds., pp. 501–504, Asilomar Conference Grounds,
Pacific Grove, Calif, USA, June 2014.
[81] Y. Su, X. Wang, J. Enitra et al., “Host genetics and upper
genital tract disease in Chlamydia muridarum infected mice:
a forward genetic approach with translational implications,”
in Proceedings of the 13th International Symposium on Human
Chlamydial Infections, J. Schachter, G. Byrne, M. A. Chernesky,
and etal, Eds., pp. 261–264, Asilomar Conference Grounds,
Pacific Grove, Calif, USA, June 2014.
[82] D. C. Ko, K. P. Shukla, C. Fong et al., “A genome-wide in vitro
bacterial-infection screen reveals human variation in the host
response associated with inflammatory disease,” The American
Journal of Human Genetics, vol. 85, no. 2, pp. 214–227, 2009.
[83] D. C. Ko and T. J. Urban, “Understanding human variation in
infectious disease susceptibility through clinical and cellular
GWAS,” PLoS Pathogens, vol. 9, no. 8, Article ID e1003424, 2013.
[84] R. S. Stephens, S. Kalman, C. Lammel et al., “Genome sequence
of an obligate intracellular pathogen of humans: Chlamydia
trachomatis,” Science, vol. 282, no. 5389, pp. 754–759, 1998.
[85] L. Kari, W. M.Whitmire, J. H. Carlson et al., “Pathogenic diver-
sity among Chlamydia trachomatis ocular strains in nonhuman
primates is affected by subtle genomic variations,” Journal of
Infectious Diseases, vol. 197, no. 3, pp. 449–456, 2008.
[86] H. M. B. Seth-Smith, S. R. Harris, K. Persson et al., “Co-
evolution of genomes and plasmids within Chlamydia tra-
chomatis and the emergence in Sweden of a new variant strain,”
BMC Genomics, vol. 10, article 239, 2009.
[87] S. Kalman, W. Mitchell, R. Marathe et al., “Comparative
genomes of Chlamydia pneumoniae and C. trachomatis,”Nature
Genetics, vol. 21, no. 4, pp. 385–389, 1999.
[88] T. D. Read, R. C. Brunham, C. Shen et al., “Genome sequences
of Chlamydia trachomatis MoPn and Chlamydia pneumoniae
AR39,” Nucleic Acids Research, vol. 28, no. 6, pp. 1397–1406,
2000.
[89] M. Shirai, H.Hirakawa,M.Kimoto et al., “Comparison ofwhole
genome sequences of Chlamydia pneumoniae J138 from Japan
and CWL029 fromUSA,”Nucleic Acids Research, vol. 28, no. 12,
pp. 2311–2314, 2000.
[90] T. D. Read, G. S. A. Myers, R. C. Brunham et al., “Genome
sequence of Chlamydophila caviae (Chlamydia psittaci GPIC):
examining the role of niche-specific genes in the evolution of
the Chlamydiaceae,” Nucleic Acids Research, vol. 31, no. 8, pp.
2134–2147, 2003.
[91] S. R. Harris, I. N. Clarke, H. M. B. Seth-Smith et al., “Whole-
genome analysis of diverse Chlamydia trachomatis strains
identifies phylogenetic relationships masked by current clinical
typing,” Nature Genetics, vol. 44, no. 4, pp. 413–419, 2012.
[92] J. P. Gomes, W. J. Bruno, A. Nunes et al., “Evolution of Chlamy-
dia trachomatis diversity occurs by widespread interstrain
recombination involving hotspots,” Genome Research, vol. 17,
no. 1, pp. 50–60, 2007.
[93] B. M. Jeffrey, R. J. Suchland, K. L. Quinn, J. R. Davidson, W.
E. Stamm, and D. D. Rockey, “Genome sequencing of recent
clinical Chlamydia trachomatis strains identifies loci associated
with tissue tropism and regions of apparent recombination,”
Infection and Immunity, vol. 78, no. 6, pp. 2544–2553, 2010.
[94] Y. Wang, S. Kahane, L. T. Cutcliffe, R. J. Skilton, P. R. Lambden,
and I. N. Clarke, “Development of a transformation system for
chlamydia trachomatis: restoration of glycogen biosynthesis by
acquisition of a plasmid shuttle vector,” PLoS Pathogens, vol. 7,
no. 9, Article ID e1002258, 2011.
Mediators of Inflammation 17
[95] Y. Wang, S. Kahane, L. T. Cutcliffe et al., “Genetic trans-
formation of a clinical (genital tract), plasmid-free isolate of
Chlamydia trachomatis: engineering the plasmid as a cloning
vector,” PLoS ONE, vol. 8, no. 3, Article ID e59195, 2013.
[96] Y. Wang, L. T. Cutcliffe, R. J. Skilton, K. Persson, C. Bjartling,
and I. N. Clarke, “Transformation of a plasmid-free, genital
tract isolate of Chlamydia trachomatis with a plasmid vector
carrying a deletion in CDS6 revealed that this gene regulates
inclusion phenotype,” Pathogens and Disease, vol. 67, no. 2, pp.
100–103, 2013.
[97] L. Song, J. H. Carlson, W. M. Whitmire et al., “Chlamydia tra-
chomatis plasmid-encoded pgp4 is a transcriptional regulator
of virulence-associated genes,” Infection and Immunity, vol. 81,
no. 3, pp. 636–644, 2013.
[98] L. Kari, M. M. Goheen, L. B. Randall et al., “Generation of
targeted Chlamydia trachomatis null mutants,” Proceedings of
the National Academy of Sciences of the United States of America,
vol. 108, no. 17, pp. 7189–7193, 2011.
[99] A. Omsland, J. Sager, V. Nair, D. E. Sturdevant, and T. Hack-
stadt, “Developmental stage-specific metabolic and tran-
scriptional activity of Chlamydia trachomatis in an axenic
medium,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 109, no. 48, pp. 19781–19785,
2012.
[100] H. M. B. Seth-Smith, S. R. Harris, R. J. Skilton et al., “Whole-
genome sequences of Chlamydia trachomatis directly from
clinical samples without culture,” Genome Research, vol. 23, no.
5, pp. 855–866, 2013.
[101] M. T. Christiansen, A. C. Brown, S. Kundu et al., “Whole-
genome enrichment and sequencing of Chlamydia trachomatis
directly from clinical samples,” BMC Infectious Diseases, vol. 14,
article 591, 2014.
[102] V. Borges, R. Ferreira, A. Nunes et al., “Effect of long-term
laboratory propagation on Chlamydia trachomatis genome
dynamics,” Infection, Genetics and Evolution, vol. 17, pp. 23–32,
2013.
[103] P. M. Bavoil, G. Myers, B. Ma et al., “Eco-pathogenomics of
chlamydial reproductive tract infection (EPCRTI),” in Proceed-
ings of the 13th International Symposium on Human Chlamydial
Infections, J. Schachter, G. Byrne, M. A. Chernesky et al., Eds.,
pp. 63–66, Asilomar Conference Grounds, Pacific Grove, Calif,
USA, June 2014.
[104] C. Bonner, H. D. Caldwell, J. H. Carlson et al., “Chlamydia
trachomatis virulence factor CT135 is stable in vivo but highly
polymorphic in vitro,” Pathogens and Disease, vol. 73, Article ID
ftv043, 2015.
[105] S. D. Tyler, G. A. Peters, C. Grose et al., “Genomic cartography
of varicella-zoster virus: a complete genome-based analysis
of strain variability with implications for attenuation and
phenotypic differences,” Virology, vol. 359, no. 2, pp. 447–458,
2007.
[106] D. J. Dargan, E. Douglas, C. Cunningham et al., “Sequential
mutations associated with adaptation of human cytomegalo-
virus to growth in cell culture,” Journal of General Virology, vol.
91, pp. 1535–1546, 2010.
[107] N. L. Bachmann, M. J. Sullivan, M. Jelocnik, G. S. A. Myers,
P. Timms, and A. Polkinghorne, “Culture-independent genome
sequencing of clinical samples reveals an unexpected hetero-
geneity of infections by Chlamydia pecorum,” Journal of Clinical
Microbiology, vol. 53, no. 5, pp. 1573–1581, 2015.
[108] D. Longbottom, M. Russell, S. M. Dunbar, G. E. Jones, and A. J.
Herring, “Molecular cloning and characterization of the genes
coding for the highly immunogenic cluster of 90-kilodalton
envelope proteins from the Chlamydia psittaci subtype that
causes abortion in sheep,” Infection & Immunity, vol. 66, no. 4,
pp. 1317–1324, 1998.
[109] D. R. Stothard, G. A. Toth, and B. E. Batteiger, “Polymorphic
membrane protein H has evolved in parallel with the three
disease-causing groups of Chlamydia trachomatis,” Infection
and Immunity, vol. 71, no. 3, pp. 1200–1208, 2003.
[110] J. P. Gomes, A. Nunes, W. J. Bruno, M. J. Borrego, C. Florindo,
and D. Dean, “Polymorphisms in the nine polymorphic mem-
brane proteins of Chlamydia trachomatis across all serovars:
evidence for serovar da recombination and correlation with
tissue tropism,” Journal of Bacteriology, vol. 188, no. 1, pp. 275–
286, 2006.
[111] D. D. Rockey, R. A. Heinzen, and T. Hackstadt, “Cloning and
characterization of a Chlamydia psittaci gene coding for a
protein localized in the inclusion membrane of infected cells,”
Molecular Microbiology, vol. 15, no. 4, pp. 617–626, 1995.
[112] R.-C. Hsia, Y. Pannekoek, E. Ingerowski, and P. M. Bavoil,
“Type III secretion genes identify a putative virulence locus of
Chlamydia,”Molecular Microbiology, vol. 25, no. 2, pp. 351–359,
1997.
[113] P. S. Hefty and R. S. Stephens, “Chlamydial type III secretion
system is encoded on ten operons preceded by Sigma 70-like
promoter elements,” Journal of Bacteriology, vol. 189, no. 1, pp.
198–206, 2006.
[114] H. D. Caldwell, H. Wood, D. Crane et al., “Polymorphisms in
Chlamydia trachomatis tryptophan synthase genes differentiate
between genital and ocular isolates,” The Journal of Clinical
Investigation, vol. 111, no. 11, pp. 1757–1769, 2003.
[115] H. Wood, C. Fehlner-Gardner, J. Berry et al., “Regulation of
tryptophan synthase gene expression in Chlamydia trachoma-
tis,”Molecular Microbiology, vol. 49, no. 5, pp. 1347–1359, 2003.
[116] J. H. Carlson, H. Wood, C. Roshick, H. D. Caldwell, and G.
McClarty, “In vivo and in vitro studies ofChlamydia trachomatis
TrpR:DNA interactions,”Molecular Microbiology, vol. 59, no. 6,
pp. 1678–1691, 2006.
[117] C. M. O’Connell, Y. M. AbdelRahman, E. Green et al., “Toll-
like receptor 2 activation by Chlamydia trachomatis is plas-
mid dependent, and plasmid-responsive chromosomal loci are
coordinately regulated in response to glucose limitation by C.
trachomatis but not by C. muridarum,” Infection and Immunity,
vol. 79, no. 3, pp. 1044–1056, 2011.
[118] T. Hackstadt, M. A. Scidmore-Carlson, E. I. Shaw, and E. R.
Fischer, “The Chlamydia trachomatis IncA protein is required
for homotypic vesicle fusion,” Cellular Microbiology, vol. 1, no.
2, pp. 119–130, 1999.
[119] R. J. Suchland, D. D. Rockey, J. P. Bannantine, andW. E. Stamm,
“Isolates of Chlamydia trachomatis that occupy nonfusogenic
inclusions lack IncA, a protein localized to the inclusion
membrane,” Infection and Immunity, vol. 68, no. 1, pp. 360–367,
2000.
[120] D. E. Nelson, D. D. Crane, L. D. Taylor, D. W. Dorward, M. M.
Goheen, and H. D. Caldwell, “Inhibition of chlamydiae by pri-
mary alcohols correlates with the strain-specific complement of
plasticity zone phospholipase D genes,” Infection and Immunity,
vol. 74, no. 1, pp. 73–80, 2006.
18 Mediators of Inflammation
[121] L. D. Taylor, D. E. Nelson, D. W. Dorward, W. M. Whitmire,
and H. D. Caldwell, “Biological characterization of Chlamydia
trachomatis plasticity zone MACPF domain family protein
CT153,” Infection and Immunity, vol. 78, no. 6, pp. 2691–2699,
2010.
[122] D. LaVerda, L. N. Albanese, P. E. Ruther et al., “Seroreactivity to
Chlamydia trachomatisHsp10 correlates with severity of human
genital tract disease,” Infection & Immunity, vol. 68, no. 1, pp.
303–309, 2000.
[123] A. Kol, A. H. Lichtman, R. W. Finberg, P. Libby, and E. A. Kurt-
Jones, “Cutting edge: heat shock protein (HSP) 60 activates
the innate immune response: CD14 is an essential receptor for
HSP60 activation ofmononuclear cells,” Journal of Immunology,
vol. 164, no. 1, pp. 13–17, 2000.
[124] J. H. Carlson, S. Hughes, D.Hogan et al., “Polymorphisms in the
Chlamydia trachomatis cytotoxin locus associated with ocular
and genital isolates,” Infection and Immunity, vol. 72, no. 12, pp.
7063–7072, 2004.
[125] J. H. Carlson,W.M.Whitmire, D. D. Crane et al., “The Chlamy-
dia trachomatis plasmid is a transcriptional regulator of chro-
mosomal genes and a virulence factor,” Infection and Immunity,
vol. 76, no. 6, pp. 2273–2283, 2008.
[126] L. C. Frazer, T. Darville, K. Chandra-Kuntal et al., “Plasmid-
cured Chlamydia caviae activates TLR2-dependent signaling
and retains virulence in the guinea pig model of genital tract
infection,” PLoS ONE, vol. 7, no. 1, Article ID e30747, 2012.
[127] C. Tan, J. K. Spitznagel, H.-Z. Shou et al., “The polymorphic
membrane protein gene family of the Chlamydiaciae,” in
Chlamydia: Genomics and Pathogenesis, P. M. Bavoil and P. B.
Wyrick, Eds., pp. 195–218, Horizon Bioscience, Norfolk, UK,
2006.
[128] K. A. Swanson, L. D. Taylor, S. D. Frank et al., “Chlamydia
trachomatis polymorphicmembrane proteinD is an oligomeric
autotransporter with a higher-order structure,” Infection and
Immunity, vol. 77, no. 1, pp. 508–516, 2009.
[129] W. Wehrl, V. Brinkmann, P. R. Jungblut, T. F. Meyer, and A. J.
Szczepek, “From the inside out—processing of the Chlamydial
autotransporter PmpD and its role in bacterial adhesion and
activation of human host cells,”Molecular Microbiology, vol. 51,
no. 2, pp. 319–334, 2004.
[130] R. J. Belland, M. A. Scidmore, D. D. Crane et al., “Chlamydia
trachomatis cytotoxicity associated with complete and partial
cytotoxin genes,” Proceedings of the National Academy of Sci-
ences of the United States of America, vol. 98, no. 24, pp. 13984–
13989, 2001.
[131] I. Tietzel, C. El-Haibi, and R. A. Carabeo, “Human guany-
late binding proteins potentiate the anti-chlamydia effects of
interferon-gamma,” PLoS ONE, vol. 4, no. 8, Article ID e6499,
2009.
[132] N. R. Thomson, M. T. G. Holden, C. Carder et al., “Chlamydia
trachomatis: genome sequence analysis of lymphogranuloma
venereum isolates,” Genome Research, vol. 18, no. 1, pp. 161–171,
2008.
[133] B. Fan, B. van der Pol, andD.Nelson, “Do chlamydial cytotoxins
mediate IFN-𝛾 immune evasion,” in Proceedings of the European
Society for Chlamydia Research, vol. 6, pp. 165–171, 2008.
[134] M. Sait, M. Livingstone, E. M. Clark et al., “Genome sequenc-
ing and comparative analysis of three Chlamydia pecorum
strains associated with different pathogenic outcomes,” BMC
Genomics, vol. 15, article 23, 2014.
[135] A. Ciervo, F. Mancini, and A. Cassone, “Transcription, expres-
sion, localization and immunoreactivity of Chlamydophila
pneumoniae Phospholipase D protein,” Microbial Pathogenesis,
vol. 43, no. 2, pp. 96–105, 2007.
[136] D. R. Clifton, K. A. Fields, S. S. Grieshaber et al., “A chlamydial
type III translocated protein is tyrosine-phosphorylated at
the site of entry and associated with recruitment of actin,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 101, no. 27, pp. 10166–10171, 2004.
[137] W. M. Geisler, R. J. Suchland, D. D. Rockey, and W. E. Stamm,
“Epidemiology and clinical manifestations of unique Chlamy-
dia trachomatis isolates that occupy nonfusogenic inclusions,”
Journal of Infectious Diseases, vol. 184, no. 7, pp. 879–884, 2001.
[138] K. M. Mirrashidi, C. A. Elwell, E. Verschueren et al., “Global
mapping of the inc-human interactome reveals that retromer
restricts Chlamydia infection,” Cell Host & Microbe, vol. 18, no.
1, pp. 109–121, 2015.
[139] C. J. Hueck, “Type III protein secretion systems in bacterial
pathogens of animals and plants,” Microbiology and Molecular
Biology Reviews, vol. 62, no. 2, pp. 379–433, 1998.
[140] J. J.Mecsas andE. J. Strauss, “Molecularmechanisms of bacterial
virulence: type III secretion and pathogenicity islands,” Emerg-
ing Infectious Diseases, vol. 2, no. 4, pp. 270–288, 1996.
[141] I. M. Sigar, J. H. Schripsema, Y.Wang et al., “Plasmid deficiency
in urogenital isolates of Chlamydia trachomatis reduces infec-
tivity and virulence in a mouse model,” Pathogens and Disease,
vol. 70, no. 1, pp. 61–69, 2014.
[142] M. Russell, T. Darville, K. Chandra-Kuntal, B. Smith, C. W.
Andrews Jr., and C. M. O’Connell, “Infectivity acts as in vivo
selection for maintenance of the chlamydial cryptic plasmid,”
Infection and Immunity, vol. 79, no. 1, pp. 98–107, 2011.
[143] A. R. Last, C. H. Roberts, E. Cassama et al., “Plasmid copy
number and disease severity in naturally occurring ocular
Chlamydia trachomatis infection,” Journal of Clinical Microbi-
ology, vol. 52, no. 1, pp. 324–327, 2014.
[144] A. J. Twigg and D. Sherratt, “Trans-complementable copy-
number mutants of plasmid ColE1,” Nature, vol. 283, no. 5743,
pp. 216–218, 1980.
[145] N. S.Thomas,M. Lusher, C. C. Storey, and I. N. Clarke, “Plasmid
diversity in Chlamydia,” Microbiology, vol. 143, no. 6, pp. 1847–
1854, 1997.
[146] Q. An, G. Radcliffe, R. Vassallo et al., “Infection with a plasmid-
free variant chlamydia related to Chlamydia trachomatis identi-
fied by using multiple assays for nucleic acid detection,” Journal
of Clinical Microbiology, vol. 30, no. 11, pp. 2814–2821, 1992.
[147] E.M. Peterson, B. A.Markoff, J. Schachter, and L.M. de laMaza,
“The 7.5-kb plasmid present in Chlamydia trachomatis is not
essential for the growth of this microorganism,” Plasmid, vol.
23, no. 2, pp. 144–148, 1990.
[148] S. F. Porcella, J. H. Carlson, D. E. Sturdevant et al., “Transcrip-
tional profiling of human epithelial cells infected with plasmid-
bearing and plasmid-deficient Chlamydia trachomatis,” Infec-
tion and Immunity, vol. 83, no. 2, pp. 534–543, 2015.
[149] M. Laabei, M. Recker, J. K. Rudkin et al., “Predicting the viru-
lence of MRSA from its genome sequence,” Genome Research,
vol. 24, no. 5, pp. 839–849, 2014.
[150] T. D. Read and R. C. Massey, “Characterizing the genetic basis
of bacterial phenotypes using genome-wide association studies:
a new direction for bacteriology,” Genome Medicine, vol. 6, no.
11, article 109, 2014.
Mediators of Inflammation 19
[151] S. K. Sheppard, X. Didelot, G. Meric et al., “Genome-wide
association study identifies vitamin B5 biosynthesis as a host
specificity factor in Campylobacter,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 110, no.
29, pp. 11923–11927, 2013.
[152] M. R. Farhat, B. J. Shapiro, K. J. Kieser et al., “Genomic analysis
identifies targets of convergent positive selection in drug-
resistant Mycobacterium tuberculosis,” Nature Genetics, vol. 45,
no. 10, pp. 1183–1189, 2013.
[153] M. T. Alam, R. A. Petit, E. K. Crispell et al., “Dissecting van-
comycin-intermediate resistance in Staphylococcus aureus using
genome-wide association,” Genome Biology and Evolution, vol.
6, no. 5, pp. 1174–1185, 2014.
[154] C. Chewapreecha, P. Marttinen, N. J. Croucher et al., “Com-
prehensive identification of single nucleotide polymorphisms
associated with beta-lactam resistance within pneumococcal
mosaic genes,” PLoS Genetics, vol. 10, no. 8, Article ID e1004547,
2014.
[155] V. H. Hu, P. Massae, H. A. Weiss et al., “Bacterial infection
in scarring trachoma,” Investigative Ophthalmology & Visual
Science, vol. 52, pp. 2181–2186, 2011.
[156] M. J. Burton, R. A.Adegbola, F. Kinteh et al., “Bacterial infection
and trachoma in the Gambia: a case-control study,” Investigative
Ophthalmology and Visual Science, vol. 48, no. 10, pp. 4440–
4444, 2007.
[157] V. Cevallos, J. P. Whitcher, M. Melese et al., “Association of
conjunctival bacterial infection and female sex in cicatricial
trachoma,” Investigative Ophthalmology & Visual Science, vol.
53, no. 9, pp. 5208–5212, 2012.
[158] M. J. Burton, V. H. Hu, P. Massae et al., “What Is causing active
trachoma? The role of nonchlamydial bacterial pathogens in a
low prevalence setting,” Investigative Ophthalmology and Visual
Science, vol. 52, no. 8, pp. 6012–6017, 2011.
[159] S. E. Burr, J. D. Hart, T. Edwards et al., “Association between
ocular bacterial carriage and follicular trachoma following
mass azithromycin distribution inTheGambia,” PLoS Neglected
Tropical Diseases, vol. 7, no. 7, Article ID e2347, 2013.
[160] M. J. Burton, R. J. C. Bowman, H. Faal et al., “Long term
outcome of trichiasis surgery in the Gambia,” British Journal of
Ophthalmology, vol. 89, no. 5, pp. 575–579, 2005.
[161] M. J. Burton, R. L. Bailey, D. Jeffries et al., “Conjunctival expres-
sion ofmatrixmetalloproteinase andproinflammatory cytokine
genes after trichiasis surgery,” Investigative Ophthalmology and
Visual Science, vol. 51, no. 7, pp. 3583–3590, 2010.
[162] D. N. Frank, A. L. St Amand, R. A. Feldman, E. C. Boedeker,
N. Harpaz, and N. R. Pace, “Molecular-phylogenetic character-
ization of microbial community imbalances in human inflam-
matory bowel diseases,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 104, no. 34, pp.
13780–13785, 2007.
[163] B. Willing, J. Halfvarson, J. Dicksved et al., “Twin studies
reveal specific imbalances in the mucosa-associated microbiota
of patients with ileal Crohn’s disease,” Inflammatory Bowel
Diseases, vol. 15, no. 5, pp. 653–660, 2009.
[164] A. W. Walker, J. D. Sanderson, C. Churcher et al., “High-
throughput clone library analysis of the mucosa-associated
microbiota reveals dysbiosis and differences between inflamed
and non-inflamed regions of the intestine in inflammatory
bowel disease,” BMCMicrobiology, vol. 11, article 7, 2011.
[165] A. J. McDermott and G. B. Huffnagle, “The microbiome and
regulation of mucosal immunity,” Immunology, vol. 142, no. 1,
pp. 24–31, 2014.
[166] M. Valentini, A. Piermattei, G. Di Sante, G.Migliara, G. Delogu,
and F. Ria, “Immunomodulation by gut microbiota: role of
Toll-like receptor expressed by T cells,” Journal of Immunology
Research, vol. 2014, Article ID 586939, 8 pages, 2014.
[167] M.M. Kosiewicz, A. L. Zirnheld, and P. Alard, “Gut microbiota,
immunity, and disease: a complex relationship,” Frontiers in
Microbiology, vol. 2, article 180, 2011.
[168] N. Van Oostrum, P. De Sutter, J. Meys, and H. Verstraelen,
“Risks associated with bacterial vaginosis in infertility patients:
a systematic review and meta-analysis,” Human Reproduction,
vol. 28, no. 7, pp. 1809–1815, 2013.
[169] S. D. Spandorfer, A.Neuer, P. C. Giraldo, Z. Rosenwaks, and S. S.
Witkin, “Relationship of abnormal vaginal flora, proinflamma-
tory cytokines and idiopathic infertility in women undergoing
IVF,” Journal of Reproductive Medicine for the Obstetrician and
Gynecologist, vol. 46, no. 9, pp. 806–810, 2001.
[170] Q. Dong, J. M. Brulc, A. Iovieno et al., “Diversity of bacteria
at healthy human conjunctiva,” Investigative Ophthalmology and
Visual Science, vol. 52, no. 8, pp. 5408–5413, 2011.
[171] Y. Zhou, H. Gao, K. A. Mihindukulasuriya et al., “Biogeography
of the ecosystems of the healthy human body,” Genome Biology,
vol. 14, article R1, 2013.
[172] Y. Zhou, M. J. Holland, P. Makalo et al., “The conjunctival
microbiome in health and trachomatous disease: a case control
study,” Genome Medicine, vol. 6, article 99, 2014.
[173] R. P. Dickson, J. R. Erb-Downward, and G. B. Huffnagle, “The
role of the bacterial microbiome in lung disease,” Expert Review
of Respiratory Medicine, vol. 7, no. 3, pp. 245–257, 2013.
[174] D.-P. Mao, Q. Zhou, C.-Y. Chen, and Z.-X. Quan, “Coverage
evaluation of universal bacterial primers using the metage-
nomic datasets,” BMCMicrobiology, vol. 12, article 66, 2012.
[175] G. Dubourg, J. C. Lagier, F. Armougom et al., “The gut micro-
biota of a patientwith resistant tuberculosis ismore comprehen-
sively studied by culturomics than bymetagenomics,” European
Journal of Clinical Microbiology and Infectious Diseases, vol. 32,
no. 5, pp. 637–645, 2013.
[176] A. A. Pezzulo, P. H. Kelly, B. S. Nassar et al., “Abundant dnase I-
sensitive bacterial DNA in healthy porcine lungs and its impli-
cations for the lung microbiome,” Applied and Environmental
Microbiology, vol. 79, no. 19, pp. 5936–5941, 2013.
[177] J.-C. Lagier, F. Armougom, M. Million et al., “Microbial cul-
turomics: paradigm shift in the human gut microbiome study,”
Clinical Microbiology and Infection, vol. 18, no. 12, pp. 1185–1193,
2012.
[178] J.-C. Lagier,M.Million, P. Hugon, F. Armougom, andD. Raoult,
“Human gut microbiota: repertoire and variations,” Frontiers in
Cellular and Infection Microbiology, vol. 2, article 136, 2012.
[179] A. Omsland, T. Hackstadt, and R. A. Heinzen, “Bringing culture
to the uncultured: Coxiella burnetii and lessons for obligate
intracellular bacterial pathogens,” PLoS Pathogens, vol. 9, no. 9,
Article ID e1003540, 2013.
[180] N. W. Palm, M. R. de Zoete, T. W. Cullen et al., “Immunoglob-
ulin A coating identifies colitogenic bacteria in inflammatory
bowel disease,” Cell, vol. 158, no. 5, pp. 1000–1010, 2014.
[181] A. L. Kau, J. D. Planer, J. Liu et al., “Functional characterization
of IgA-targeted bacterial taxa from undernourished Malawian
children that produce diet-dependent enteropathy,” Science
Translational Medicine, vol. 7, no. 276, Article ID 276ra24, 2015.
20 Mediators of Inflammation
[182] H. Bierne,M.Hamon, and P. Cossart, “Epigenetics and bacterial
infections,” Cold Spring Harbor Perspectives in Medicine, 2012.
[183] S.-H. Shin, S.-Y. Park, J.-S. Ko, N. Kim, and G. H. Kang, “Aber-
rant CpG island hypermethylation in pediatric gastric mucosa
in association with helicobacter pylori infection,” Archives of
Pathology & Laboratory Medicine, vol. 135, no. 6, pp. 759–765,
2011.
[184] F.-Y. Huang, A. O.-O. Chan, A. Rashid, D. K.-H. Wong, C.-
H. Cho, and M.-F. Yuen, “Helicobacter pylori induces promoter
methylation of E-cadherin via interleukin-1𝛽 activation of nitric
oxide production in gastric cancer cells,”Cancer, vol. 118, no. 20,
pp. 4969–4980, 2012.
[185] J. Kleinnijenhuis, J. Quintin, F. Preijers et al., “Bacille Calmette-
Gue´rin induces NOD2-dependent nonspecific protection from
reinfection via epigenetic reprogramming of monocytes,” Pro-
ceedings of the National Academy of Sciences of the United States
of America, vol. 109, no. 43, pp. 17537–17542, 2012.
[186] M.Murata, Y. Azuma, K.Miura et al., “Chlamydial SET domain
protein functions as a histone methyltransferase,”Microbiology,
vol. 153, no. 2, pp. 585–592, 2007.
[187] M. E. Pennini, S. Perrinet, A. Dautry-Varsat, and A. Subtil,
“Histone methylation by NUE, a novel nuclear effector of the
intracellular pathogenChlamydia trachomatis,”PLoS Pathogens,
vol. 6, no. 7, Article ID e1000995, pp. 1–12, 2010.
[188] M. S. Humphrys, T. Creasy, Y. Sun et al., “Simultaneous
transcriptional profiling of bacteria and their host cells,” PLoS
ONE, vol. 8, no. 12, Article ID e80597, 2013.
[189] P. Kapranov, J. Cheng, S. Dike et al., “RNA maps reveal new
RNA classes and a possible function for pervasive transcrip-
tion,” Science, vol. 316, no. 5830, pp. 1484–1488, 2007.
[190] R. C. Friedman, K. K.-H. Farh, C. B. Burge, and D. P. Bartel,
“Most mammalian mRNAs are conserved targets of microR-
NAs,” Genome Research, vol. 19, no. 1, pp. 92–105, 2009.
[191] J. Martinez, A. Patkaniowska, H. Urlaub, R. Lu¨hrmann, and T.
Tuschl, “Single-stranded antisense siRNAs guide target RNA
cleavage in RNAi,” Cell, vol. 110, no. 5, pp. 563–574, 2002.
[192] C. E. Vejnar and E.M. Zdobnov, “11673,”Nucleic Acids Research,
vol. 40, no. 22, pp. 11673–11683, 2012.
[193] D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism,
and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004.
[194] V. Ambros, “The functions of animal microRNAs,” Nature, vol.
431, no. 7006, pp. 350–355, 2004.
[195] S. Memczak, M. Jens, A. Elefsinioti et al., “Circular RNAs are
a large class of animal RNAs with regulatory potency,” Nature,
vol. 495, no. 7441, pp. 333–338, 2013.
[196] T. B. Hansen, T. I. Jensen, B. H. Clausen et al., “Natural RNA
circles function as efficient microRNA sponges,” Nature, vol.
495, no. 7441, pp. 384–388, 2013.
[197] M. Van Kouwenhove, M. Kedde, and R. Agami, “MicroRNA
regulation by RNA-binding proteins and its implications for
cancer,”Nature Reviews Cancer, vol. 11, no. 9, pp. 644–656, 2011.
[198] S. R. Viswanathan, G. Q. Daley, and R. I. Gregory, “Selective
blockade of microRNA processing by Lin28,” Science, vol. 320,
no. 5872, pp. 97–100, 2008.
[199] C. Staedel and F. Darfeuille, “MicroRNAs and bacterial infec-
tion,” Cellular Microbiology, vol. 15, no. 9, pp. 1496–1507, 2013.
[200] A. Eulalio, L. N. Schulte, and J. Voge, “The mammalian
microRNA response to bacterial infections,” RNA Biology, vol.
9, no. 6, pp. 742–750, 2012.
[201] C. Maudet, M. Mano, and A. Eulalio, “microRNAs in the inter-
action between host and bacterial pathogens,” FEBS Letters, vol.
588, no. 22, pp. 4140–4147, 2014.
[202] L. Yeruva, G. S. Myers, N. Spencer et al., “Early microRNA
expression profile as a prognostic biomarker for the devel-
opment of pelvic inflammatory disease in a mouse model of
chlamydial genital infection,” mBio, vol. 5, no. 3, Article ID
e01241-14, 2014.
[203] R. Gupta, T. Arkatkar, J.-J. Yu et al., “Chlamydia muridarum
infection associated hostMicroRNAs in themurine genital tract
and contribution to generation of host immune response,” The
American Journal of Reproductive Immunology, vol. 73, no. 2, pp.
126–140, 2015.
[204] R. L. Rossi, G. Rossetti, L. Wenandy et al., “Distinct microRNA
signatures in human lymphocyte subsets and enforcement of
the naive state in CD4+ T cells by the microRNA miR-125b,”
Nature Immunology, vol. 12, no. 8, pp. 796–803, 2011.
[205] J. U. Igietseme, Y. Omosun, J. Partin et al., “Prevention of
chlamydia-induced infertility by inhibition of local caspase
activity,” The Journal of Infectious Diseases, vol. 207, no. 7, pp.
1095–1104, 2013.
[206] W. Zhang, X. Yi, S. Guo et al., “A single-nucleotide polymor-
phism of miR-146a and psoriasis: an association and functional
study,” Journal of Cellular andMolecularMedicine, vol. 18, no. 11,
pp. 2225–2234, 2014.
[207] W. Wang, F. R. Stassen, H.-M. Surcel et al., “Analyses of
polymorphisms in the inflammasome-associated NLRP3 and
miRNA-146A genes in the susceptibility to and tubal pathology
ofChlamydia trachomatis infection,”Drugs of Today, vol. 45, pp.
95–103, 2009.
[208] T. Derrick, C. h. Roberts, M. Rajasekhar et al., “Conjunctival
MicroRNA expression in inflammatory trachomatous scar-
ring,” PLoS Neglected Tropical Diseases, vol. 7, no. 3, p. e2117,
2013.
[209] G. Liu, A. Friggeri, Y. Yang, Y.-J. Park, Y. Tsuruta, and E.
Abraham, “miR-147, a microRNA that is induced upon toll-like
receptor stimulation, regulates murine macrophage inflamma-
tory responses,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 106, no. 37, pp. 15819–15824,
2009.
[210] T. Bertero, S. Grosso, K. Robbe-Sermesant et al., “‘Seed-
milarity’ confers to hsa-miR-210 and hsa-miR-147b similar
functional activity,” PLoS ONE, vol. 7, Article ID e44919, 2012.
[211] S. Tian, S. Huang, S. Wu, W. Guo, J. Li, and X. He, “MicroRNA-
1285 inhibits the expression of p53 by directly targeting its
3󸀠 untranslated region,” Biochemical and Biophysical Research
Communications, vol. 396, no. 2, pp. 435–439, 2010.
[212] H. Hidaka, N. Seki, H. Yoshino et al., “Tumor suppressive
microRNA-1285 regulates novel molecular targets: aberrant
expression and functional significance in renal cell carcinoma,”
Oncotarget, vol. 3, no. 1, pp. 44–57, 2012.
[213] B. R. Cullen, “Viruses andmicroRNAs: RISCy interactions with
serious consequences,”Genes &Development, vol. 25, no. 18, pp.
1881–1894, 2011.
[214] W. de Vries and B. Berkhout, “RNAi suppressors encoded
by pathogenic human viruses,” The International Journal of
Biochemistry &Cell Biology, vol. 40, no. 10, pp. 2007–2012, 2008.
[215] M. Kumar, S. K. Sahu, R. Kumar et al., “microRNA let-7 mod-
ulates the immune response to Mycobacterium tuberculosis
infection via control of A20, an inhibitor of theNF-𝜅Bpathway,”
Cell Host & Microbe, vol. 17, no. 3, pp. 345–356, 2015.
Mediators of Inflammation 21
[216] A. H. Buck, G. Coakley, F. Simbari et al., “Exosomes secreted
by nematode parasites transfer small RNAs to mammalian cells
and modulate innate immunity,” Nature Communications, vol.
5, article 5488, 2014.
[217] Y. Furuse, R. Finethy, H. A. Saka et al., “Search for microRNAs
expressed by intracellular bacterial pathogens in infectedmam-
malian cells,” PLoS ONE, vol. 9, no. 9, Article ID e106434, 2014.
[218] Y.M.Abdelrahman, L.A. Rose, andR. J. Belland, “Developmen-
tal expression of non-coding RNAs in Chlamydia trachomatis
during normal and persistent growth,” Nucleic Acids Research,
vol. 39, no. 5, pp. 1843–1854, 2011.
[219] M. Albrecht, C. M. Sharma, R. Reinhardt, J. Vogel, and T.
Rudel, “Deep sequencing-based discovery of the Chlamydia
trachomatis transcriptome,” Nucleic Acids Research, vol. 38, no.
3, Article ID gkp1032, pp. 868–877, 2009.
[220] S. Ricci, R. Cevenini, E. Cosco,M. Comanducci, G. Ratti, and V.
Scarlato, “Transcriptional analysis of theChlamydia trachomatis
plasmid pCT identifies temporally regulated transcripts, anti-
sense RNA and 𝜎70-selected promoters,” Molecular & General
Genetics, vol. 237, no. 3, pp. 318–326, 1993.
[221] R. Kalluri and R. A. Weinberg, “The basics of epithelial-
mesenchymal transition,” The Journal of Clinical Investigation,
vol. 119, no. 6, pp. 1420–1428, 2009.
[222] M. Zeisberg and E. G. Neilson, “Biomarkers for epithelial-
mesenchymal transitions,” Journal of Clinical Investigation, vol.
119, no. 6, pp. 1429–1437, 2009.
[223] E. M. Zeisberg, O. Tarnavski, M. Zeisberg et al., “Endothelial-
to-mesenchymal transition contributes to cardiac fibrosis,”
Nature Medicine, vol. 13, no. 8, pp. 952–961, 2007.
[224] H. Okada, F. Strutz, T. M. Danoff, R. Kalluri, and E. G. Neil-
son, “Possible mechanisms of renal fibrosis,” Contributions to
Nephrology, vol. 118, pp. 147–154, 1996.
[225] M. Iwano, D. Plieth, T. M. Danoff, C. Xue, H. Okada, and E.
G. Neilson, “Evidence that fibroblasts derive from epithelium
during tissue fibrosis,”The Journal of Clinical Investigation, vol.
110, no. 3, pp. 341–350, 2002.
[226] M. Chilosi, V. Poletti, A. Zamo` et al., “Aberrant Wnt/beta-
catenin pathway activation in idiopathic pulmonary fibrosis,”
American Journal of Pathology, vol. 162, no. 5, pp. 1495–1502,
2003.
[227] M. Zeisberg, C. Yang, M. Martino et al., “Fibroblasts derive
from hepatocytes in liver fibrosis via epithelial to mesenchymal
transition,” Journal of Biological Chemistry, vol. 282, no. 32, pp.
23337–23347, 2007.
[228] C. Yan, W. A. Grimm, W. L. Garner et al., “Epithelial to mes-
enchymal transition in human skin wound healing is induced
by tumor necrosis factor-alpha through bone morphogenic
protein-2,” American Journal of Pathology, vol. 176, no. 5, pp.
2247–2258, 2010.
[229] J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, “Epi-
thelial-mesenchymal transitions in development and disease,”
Cell, vol. 139, no. 5, pp. 871–890, 2009.
[230] A.-P. Morel, M. Lie`vre, C. Thomas, G. Hinkal, S. Ansieau, and
A. Puisieux, “Generation of breast cancer stem cells through
epithelial-mesenchymal transition,” PLoS ONE, vol. 3, no. 8,
Article ID e2888, 2008.
[231] U. Wellner, J. Schubert, U. C. Burk et al., “The EMT-activator
ZEB1 promotes tumorigenicity by repressing stemness-
inhibiting microRNAs,” Nature Cell Biology, vol. 11, no. 12, pp.
1487–1495, 2009.
[232] S. A. Mani, W. Guo, M.-J. Liao et al., “The epithelial-mesenchy-
mal transition generates cells with properties of stem cells,”Cell,
vol. 133, no. 4, pp. 704–715, 2008.
[233] O. G. McDonald, H. Wu, W. Timp, A. Doi, and A. P. Feinberg,
“Genome-scale epigenetic reprogramming during epithelial-
to-mesenchymal transition,” Nature Structural & Molecular
Biology, vol. 18, no. 8, pp. 867–874, 2011.
[234] M. Lombaerts, T. van Wezel, K. Philippo et al., “E-cadherin
transcriptional downregulation by promoter methylation but
not mutation is related to epithelial-to-mesenchymal transition
in breast cancer cell lines,” British Journal of Cancer, vol. 94, no.
5, pp. 661–671, 2006.
[235] N. Dumont, M. B. Wilson, Y. G. Crawford, P. A. Reynolds, M.
Sigaroudinia, and T. D. Tlsty, “Sustained induction of epithelial
to mesenchymal transition activates DNAmethylation of genes
silenced in basal-like breast cancers,”Proceedings of the National
Academy of Sciences of the United States of America, vol. 105, no.
39, pp. 14867–14872, 2008.
[236] S.-O. Lim, J.-M. Gu, M. S. Kim et al., “Epigenetic changes
induced by reactive oxygen species in hepatocellular carcinoma:
methylation of the E-cadherin promoter,”Gastroenterology, vol.
135, no. 6, pp. 2128–2140.e8, 2008.
[237] H. Peinado, E. Ballestar, M. Esteller, and A. Cano, “Snail medi-
ates E-cadherin repression by the recruitment of the Sin3A/
histone deacetylase 1 (HDAC1)/HDAC2 complex,” Molecular
and Cellular Biology, vol. 24, no. 1, pp. 306–319, 2004.
[238] S. K. Bose, K. Meyer, A. M. Di Bisceglie, R. B. Ray, and R. Ray,
“Hepatitis C virus induces epithelial-mesenchymal transition in
primary human hepatocytes,” Journal of Virology, vol. 86, no. 24,
pp. 13621–13628, 2012.
[239] L. Zhao, R. Yang, L. Cheng, M. Wang, Y. Jiang, and S. Wang,
“LPS-induced epithelial-mesenchymal transition of intrahep-
atic biliary epithelial cells,” Journal of Surgical Research, vol. 171,
no. 2, pp. 819–825, 2011.
[240] V. Pozharskaya, E. Torres-Gonza´lez, M. Rojas et al., “Twist: a
regulator of epithelial-mesenchymal transition in lung fibrosis,”
PLoS ONE, vol. 4, no. 10, Article ID e7559, 2009.
[241] G. Cane, A. Ginouve`s, S. Marchetti et al., “HIF-1alpha mediates
the induction of IL-8 and VEGF expression on infection
with Afa/Dr diffusely adhering E. coli and promotes EMT-like
behaviour,” Cellular Microbiology, vol. 12, no. 5, pp. 640–653,
2010.
[242] E. Papini, B. Satin, N. Norais et al., “Selective increase of
the permeability of polarized epithelial cell monolayers by
Helicobacter pylori vacuolating toxin,” The Journal of Clinical
Investigation, vol. 102, no. 4, pp. 813–820, 1998.
[243] M. R. Amieva, R. Vogetmann, A. Covacci, L. S. Tompkins, W.
J. Nelson, and S. Falkow, “Disruption of the epithelial apical-
junctional complex by Helicobacter pylori CagA,” Science, vol.
300, no. 5624, pp. 1430–1434, 2003.
[244] N. Murata-Kamiya, Y. Kurashima, Y. Teishikata et al., “Heli-
cobacter pylori CagA interacts with E-cadherin and deregulates
the 𝛽-catenin signal that promotes intestinal transdifferentia-
tion in gastric epithelial cells,” Oncogene, vol. 26, no. 32, pp.
4617–4626, 2007.
[245] F. Yin, A. M. Grabowska, P. A. Clarke et al., “Helicobacter pylori
potentiates epithelial:mesenchymal transition in gastric cancer:
links to soluble HB-EGF, gastrin andmatrix metalloproteinase-
7,” Gut, vol. 59, no. 8, pp. 1037–1045, 2010.
22 Mediators of Inflammation
[246] J. Baud, C. Varon, S. Chabas, L. Chambonnier, F. Darfeuille,
and C. Staedel, “Helicobacter pylori initiates a mesenchymal
transition through ZEB1 in gastric epithelial cells,” PLoS ONE,
vol. 8, no. 4, Article ID e60315, 2013.
[247] M. Kessler, J. Zielecki, O. Thieck, H.-J. Mollenkopf, C. Foto-
poulou, and T. F. Meyer, “Chlamydia trachomatis disturbs
epithelial tissue homeostasis in fallopian tubes via paracrine
Wnt signaling,” American Journal of Pathology, vol. 180, no. 1,
pp. 186–198, 2012.
[248] W. C. Prozialeck, M. J. Fay, P. C. Lamar, C. A. Pearson, I. Sigar,
and K. H. Ramsey, “Chlamydia trachomatis disrupts N-cad-
herin-dependent cell-cell junctions and sequesters beta-catenin
in human cervical epithelial cells,” Infection and Immunity, vol.
70, no. 5, pp. 2605–2613, 2002.
[249] J. Sun, J. Kintner, and R. V. Schoborg, “The host adherens
junction molecule nectin-1 is downregulated in Chlamydia
trachomatis-infected genital epithelial cells,” Microbiology, vol.
154, no. 5, pp. 1290–1299, 2008.
[250] M. J. Holland, D. Jeffries, M. Pattison et al., “Pathway-focused
arrays reveal increasedmatrix metalloproteinase-7 (Matrilysin)
transcription in trachomatous trichiasis,” Investigative Ophthal-
mology and Visual Science, vol. 51, no. 8, pp. 3893–3902, 2010.
[251] H.-C. Chen, Y.-T. Zhu, S.-Y. Chen, and S. C. G. Tseng, “Wnt
signaling induces epithelial-mesenchymal transition with pro-
liferation in ARPE-19 cells upon loss of contact inhibition,”
Laboratory Investigation, vol. 92, no. 5, pp. 676–687, 2012.
[252] D. A. Cusanovich, C. Billstrand, X. Zhou et al., “The com-
bination of a genome-wide association study of lymphocyte
count and analysis of gene expression data reveals novel asthma
candidate genes,” Human Molecular Genetics, vol. 21, no. 9, pp.
2111–2123, 2012.
[253] P. Jia and Z. Zhao, “Network-assisted analysis to prioritize
GWAS results: principles, methods and perspectives,” Human
Genetics, vol. 133, no. 2, pp. 125–138, 2014.
[254] P. Holmans, E. K. Green, J. S. Pahwa et al., “Gene ontology
analysis of GWA study data sets provides insights into the
biology of bipolar disorder,” The American Journal of Human
Genetics, vol. 85, no. 1, pp. 13–24, 2009.
[255] R. Braun and K. Buetow, “Pathways of distinction analysis: a
new technique for multi-SNP analysis of GWAS data,” PLoS
Genetics, vol. 7, no. 6, Article ID e1002101, 2011.
[256] C. S. Greene, N.M. Penrod, J. Kiralis, and J. H.Moore, “Spatially
uniform reliefF (SURF) for computationally-efficient filtering
of gene-gene interactions,” BioData Mining, vol. 2, article 5,
2009.
[257] M. D. Ritchie, L. W. Hahn, N. Roodi et al., “Multifactor-dimen-
sionality reduction reveals high-order interactions among
estrogen-metabolism genes in sporadic breast cancer,” The
American Journal of Human Genetics, vol. 69, no. 1, pp. 138–147,
2001.
[258] P. Jia and Z. Zhao, “Searching joint association signals in CATIE
schizophrenia genome-wide association studies through a
refined integrative network approach,” BMC Genomics, vol. 13,
supplement 6, article S15, 2012.
[259] S. Purcell, B. Neale, K. Todd-Brown et al., “PLINK: a tool set
for whole-genome association and population-based linkage
analyses,”The American Journal of Human Genetics, vol. 81, no.
3, pp. 559–575, 2007.
[260] L. S. Chen, C. M. Hutter, J. D. Potter et al., “Insights into colon
cancer etiology via a regularized approach to gene set analysis
of GWAS data,” The American Journal of Human Genetics, vol.
86, no. 6, pp. 860–871, 2010.
[261] D. Knights, M. S. Silverberg, R. K. Weersma et al., “Complex
host genetics influence the microbiome in inflammatory bowel
disease,” Genome Medicine, vol. 6, article 107, 2014.
[262] B. P. Fairfax, S. Makino, J. Radhakrishnan et al., “Genetics of
gene expression in primary immune cells identifies cell type-
specific master regulators and roles of HLA alleles,” Nature
Genetics, vol. 44, no. 5, pp. 502–510, 2012.
[263] D. Wong, W. Lee, P. Humburg et al., “Genomic mapping of the
MHC transactivator CIITA using an integrated ChIP-seq and
genetical genomics approach,” Genome Biology, vol. 15, no. 10,
p. 494, 2014.
[264] D. E. Sturdevant, K. Virtaneva, C. Martens et al., “Host-
microbe interaction systems biology: lifecycle transcriptomics
and comparative genomics,” Future Microbiology, vol. 5, no. 2,
pp. 205–219, 2010.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
